Felix Feng, MD

Title(s)Professor, Radiation Oncology
SchoolSchool of Medicine
Address1450 Third Street, #383
San Francisco CA 94158
PronounsHe/Him/His
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stanford University, Stanford, CAB.S.06/1998Biological Sciences
    Washington University School of Medicine, St. Louis, MOM.D.06/2002Medicine
    University of Michigan, Ann Arbor, MIResidency06/2010Radiation Oncology

    Collapse Research 
    Collapse Research Activities and Funding
    Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer
    NIH R01CA240582Jul 1, 2020 - Jun 30, 2025
    Role: Principal Investigator
    MELT: Modulation of PSMA Expression for Lutetium Therapy
    NIH R01CA235741Jul 1, 2019 - Jun 30, 2025
    Role: Co-Principal Investigator
    Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies
    NIH R01CA227025Dec 14, 2018 - Nov 30, 2023
    Role: Co-Principal Investigator
    DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications
    NIH R01CA230516Sep 1, 2018 - Aug 31, 2023
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Collaboration Interests

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol. 2024 Sep 03; JCO2302510. Dahl DM, Rodgers JP, Shipley WU, Michaelson MD, Wu CL, Parker W, Jani AB, Cury FL, Hudes RS, Michalski JM, Hartford AC, Song D, Citrin DE, Karrison TG, Sandler HM, Feng FY, Efstathiou JA. PMID: 39226514.
      View in: PubMed   Mentions:
    2. Delayed definitive management of localized prostate cancer: what do we know? Prostate Cancer Prostatic Dis. 2024 Aug 11. Mohamad O, Li YR, Feng F, Hong JC, Wong A, El Kouzi Z, Shelan M, Zilli T, Carroll P, Roach M. PMID: 39128937.
      View in: PubMed   Mentions:    Fields:    
    3. HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. Oncologist. 2024 Aug 05; 29(8):e1094-e1097. Zhu X, Chan E, Turski ML, Mendez CE, Hsu SC, Kumar V, Shipp C, Jindal T, Chang K, Onodera C, Devine WP, Grenert JP, Stohr BA, Ding CC, Stachler MD, Quigley DA, Feng FY, Chu CE, Porten SP, Chou J, Friedlander TW, Koshkin VS. PMID: 38908022; PMCID: PMC11299940.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer. Cancer Discov. 2024 Aug 02; 14(8):1496-1521. Xu Y, Yang Y, Wang Z, Sjöström M, Jiang Y, Tang Y, Cheng S, Deng S, Wang C, Gonzalez J, Johnson NA, Li X, Li X, Metang LA, Mukherji A, Xu Q, Tirado CR, Wainwright G, Yu X, Barnes S, Hofstad M, Chen Y, Zhu H, Hanker AB, Raj GV, Zhu G, He HH, Wang Z, Arteaga CL, Liang H, Feng FY, Wang Y, Wang T, Mu P. PMID: 38591846; PMCID: PMC11285331.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    5. Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial. Clin Cancer Res. 2024 Aug 01; 30(15):3200-3210. Nguyen CB, Reimers MA, Perera C, Abida W, Chou J, Feng FY, Antonarakis ES, McKay RR, Pachynski RK, Zhang J, Reichert ZR, Palmbos PL, Caram MEV, Vaishampayan UN, Heath EI, Hopkins AC, Cieslik MP, Wu YM, Robinson DR, Baladandayuthapani V, Chinnaiyan AM, Alva AS. PMID: 38787530; PMCID: PMC11293970.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    6. Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer. Nat Genet. 2024 Jul 17. Zhao SG, Bootsma M, Zhou S, Shrestha R, Moreno-Rodriguez T, Lundberg A, Pan C, Arlidge C, Hawley JR, Foye A, Weinstein AS, Sjöström M, Zhang M, Li H, Chesner LN, Rydzewski NR, Helzer KT, Shi Y, West Coast Dream Team Consortium, Lynch M, Dehm SM, Lang JM, Alumkal JJ, He HH, Wyatt AW, Aggarwal R, Zwart W, Small EJ, Quigley DA, Lupien M, Feng FY. PMID: 39020220.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    7. Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized Trials. Eur Urol. 2024 Jul 17. Spratt DE, Liu VYT, Jia AY, Royce TJ, Sandler HM, Pugh SL, Tran PT, Feng FY. PMID: 39025748.
      View in: PubMed   Mentions:    Fields:    
    8. An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression. Cancer Res. 2024 Jul 11. Shrestha R, Chesner LN, Zhang M, Zhou S, Foye A, Lundberg A, Weinstein AS, Sjöström M, Zhu X, Moreno-Rodriguez T, Li H, West Coast Prostate Cancer Dream Team SC, Alumkal JJ, Aggarwal R, Small EJ, Lupien M, Quigley DA, Feng FY. PMID: 38990734.
      View in: PubMed   Mentions:    Fields:    
    9. Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection. J Nucl Med. 2024 Jul 01; 65(7):1064-1069. Yadav S, Jiang F, Kurkowska S, Saelee R, Morley A, Feng F, Aggarwal R, Lawhn-Heath C, Uribe C, Hope TA. PMID: 38724282.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]. Eur Urol. 2024 Jun 18. Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin M, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Neil Reaume M, Williams SG, Hannan R, Jones CU, Horwitz EM, Rodgers JP, Feng FY, Rosenthal SA. PMID: 38897867.
      View in: PubMed   Mentions:    Fields:    
    11. Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression. Nat Cell Biol. 2024 Jul; 26(7):1176-1186. Zhang M, Sjöström M, Cui X, Foye A, Farh K, Shrestha R, Lundberg A, Dang HX, Li H, Febbo PG, Aggarwal R, Alumkal JJ, Small EJ, SU2C/PCF West Coast Prostate Cancer Dream Team, Maher CA, Feng FY, Quigley DA. PMID: 38871824.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    12. Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review. Eur Urol. 2024 May 22. Weiner AB, Kakani P, Armstrong AJ, Bossi A, Cornford P, Feng F, Kanabur P, Karnes RJ, Mckay RR, Morgan TM, Schaeffer EM, Shore N, Tree AC, Spratt DE. PMID: 38782697.
      View in: PubMed   Mentions:    Fields:    
    13. Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer. Eur Urol. 2024 Aug; 86(2):81-87. Brookman-May SD, Buyse M, Freedland SJ, Miladinovic B, Zhang K, Fendler WP, Feng F, Sartor O, Sweeney CJ. PMID: 38762392.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 May 01; 10(5):584-591. Buyyounouski MK, Pugh SL, Chen RC, Mann MJ, Kudchadker RJ, Konski AA, Mian OY, Michalski JM, Vigneault E, Valicenti RK, Barkati M, Lawton CAF, Potters L, Monitto DC, Kittel JA, Schroeder TM, Hannan R, Duncan CE, Rodgers JP, Feng F, Sandler HM. PMID: 38483412; PMCID: PMC10941019.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    15. Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712. Eur Urol Oncol. 2024 Apr 18. Rana Z, Kamran SC, Shetty AC, Sutera P, Song Y, Bazyar S, Solanki AA, Simko JP, Pollack A, McConkey D, Kates M, Siddiqui MM, Hiken J, Earls J, Messina D, Mouw KW, Miyamoto D, Shipley WU, Michaelson MD, Zietman A, Coen JJ, Dahl DM, Jani AB, Souhami L, Chang BK, Lee RJ, Pham H, Marshall DT, Shen X, Pugh SL, Feng FY, Efstathiou JA, Tran PT, Deek MP. PMID: 38641541.
      View in: PubMed   Mentions:    Fields:    
    16. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. JU Open Plus. 2024 Apr; 2(4). Crawford ED, Bryce AH, Hussain MH, Agarwal N, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. PMID: 38774466; PMCID: PMC11108024.
      View in: PubMed   Mentions: 1  
    17. Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. JU Open Plus. 2024 Apr; 2(4). Bryce AH, Crawford ED, Agarwal N, Hussain MH, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. PMID: 38774467; PMCID: PMC11107999.
      View in: PubMed   Mentions:
    18. Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer. Adv Radiat Oncol. 2024 Jul; 9(7):101507. Sutera P, Deek MP, Deek RA, Guler OC, Hurmuz P, Reyhan M, Rowe S, Radwan N, Dipasquale S, Hrinivich WT, Lowe K, Ren L, Saraiya B, Ennis R, Hathout L, Mayer T, Deweese TL, Song DY, Kiess A, Oymak E, Pienta K, Feng F, Pomper M, Ozyigit G, Tran PT, Onal C, Phillips RM. PMID: 38799104; PMCID: PMC11127093.
      View in: PubMed   Mentions:
    19. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024 Apr 27; 403(10437):1683-1722. James ND, Tannock I, N'Dow J, Feng F, Gillessen S, Ali SA, Trujillo B, Al-Lazikani B, Attard G, Bray F, Compérat E, Eeles R, Fatiregun O, Grist E, Halabi S, Haran Á, Herchenhorn D, Hofman MS, Jalloh M, Loeb S, MacNair A, Mahal B, Mendes L, Moghul M, Moore C, Morgans A, Morris M, Murphy D, Murthy V, Nguyen PL, Padhani A, Parker C, Rush H, Sculpher M, Soule H, Sydes MR, Tilki D, Tunariu N, Villanti P, Xie LP. PMID: 38583453.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    20. CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality. bioRxiv. 2024 Mar 21. Tien JC, Chang Y, Zhang Y, Chou J, Cheng Y, Wang X, Yang J, Mannan R, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Lord CJ, Ding K, Chinnaiyan AM. PMID: 38562774; PMCID: PMC10983964.
      View in: PubMed   Mentions:
    21. Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation. Cancer Discov. 2024 Mar 01; 14(3):424-445. Franceschini GM, Quaini O, Mizuno K, Orlando F, Ciani Y, Ku SY, Sigouros M, Rothmann E, Alonso A, Benelli M, Nardella C, Auh J, Freeman D, Hanratty B, Adil M, Elemento O, Tagawa ST, Feng FY, Caffo O, Buttigliero C, Basso U, Nelson PS, Corey E, Haffner MC, Attard G, Aparicio A, Demichelis F, Beltran H. PMID: 38197680; PMCID: PMC10905672.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    22. Canonical AREs are tumor suppressive regulatory elements in the prostate. bioRxiv. 2024 Feb 27. Augello MA, Chen X, Liu D, Lin K, Hakansson A, Sjöström M, Khani F, Deonarine LD, Liu Y, Travascio-Green J, Wu J, Loda M, Feng FY, Robinson BD, Davicioni E, Sboner A, Barbieri CE. PMID: 38464162; PMCID: PMC10925218.
      View in: PubMed   Mentions:
    23. Single cell-transcriptomic analysis informs the lncRNA landscape in metastatic castration resistant prostate cancer. NPJ Genom Med. 2024 Feb 23; 9(1):14. Saha D, Dang HX, Zhang M, Quigley DA, Feng FY, Maher CA. PMID: 38396008; PMCID: PMC10891057.
      View in: PubMed   Mentions:
    24. Technical note: Errors introduced when using Dose Voxel Kernels for estimating absorbed dose from radiopharmaceutical therapies involving alpha emitters. Med Phys. 2024 Aug; 51(8):5764-5772. Tranel J, Palm S, Feng FY, St James S, Hope TA. PMID: 38314904; PMCID: PMC11298574.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202. Eur Urol Focus. 2024 Mar; 10(2):271-278. Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M, Tran PT, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA. PMID: 38307806; PMCID: PMC11257781.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial. Eur Urol Oncol. 2024 Jan 31. Ross AE, Zhang J, Huang HC, Yamashita R, Keim-Malpass J, Simko JP, DeVries S, Morgan TM, Souhami L, Dobelbower MC, McGinnis LS, Jones CU, Dess RT, Zeitzer KL, Choi K, Hartford AC, Michalski JM, Raben A, Gomella LG, Sartor AO, Rosenthal SA, Sandler HM, Spratt DE, Pugh SL, Mohamad O, Esteva A, Chen E, Schaeffer EM, Tran PT, Feng FY. PMID: 38302323; PMCID: PMC11289167.
      View in: PubMed   Mentions:    Fields:    
    27. Large tandem duplications in cancer result from transcription and DNA replication collisions. medRxiv. 2024 Jan 10. Yang Y, Badura ML, O'Leary PC, Delavan HM, Robinson TM, Egusa EA, Zhong X, Swinderman JT, Li H, Zhang M, Kim M, Ashworth A, Feng FY, Chou J, Yang L. PMID: 38260434; PMCID: PMC10802642.
      View in: PubMed   Mentions:
    28. Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). Br J Cancer. 2024 01; 130(1):53-62. Zhao JL, Antonarakis ES, Cheng HH, George DJ, Aggarwal R, Riedel E, Sumiyoshi T, Schonhoft JD, Anderson A, Mao N, Haywood S, Decker B, Curley T, Abida W, Feng FY, Knudsen K, Carver B, Lacouture ME, Wyatt AW, Rathkopf D. PMID: 37980367; PMCID: PMC10781677.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    29. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 2023 Nov; 24(11):1266-1276. Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong L, Hope TA. PMID: 37922930; PMCID: PMC10667020.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    30. Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis. JAMA Netw Open. 2023 Nov 01; 6(11):e2340787. Mahal BA, Kwak L, Xie W, Eastham JA, James ND, Sandler HM, Feng FY, Brihoum M, Fizazi K, Sweeney C, Ravi P, D'Amico AV. PMID: 37910103; PMCID: PMC10620614.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    31. ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers. bioRxiv. 2023 Oct 27. Xu Y, Wang Z, Sjöström M, Deng S, Wang C, Johnson NA, Gonzalez J, Li X, Metang LA, Tirado CR, Mukherji A, Wainwright G, Yu X, Yang Y, Barnes S, Hofstad M, Zhu H, Hanker A, He HH, Chen Y, Wang Z, Raj G, Arteaga C, Feng F, Wang Y, Wang T, Mu P. PMID: 37961351; PMCID: PMC10634771.
      View in: PubMed   Mentions:
    32. Author Correction: Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer. Nat Commun. 2023 Sep 27; 14(1):6022. Nguyen T, Sridaran D, Chouhan S, Weimholt C, Wilson A, Luo J, Li T, Koomen J, Fang B, Putluri N, Sreekumar A, Feng FY, Mahajan K, Mahajan NP. PMID: 37758702; PMCID: PMC10533897.
      View in: PubMed   Mentions:    Fields:    
    33. Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. Cell. 2023 Sep 14; 186(19):4254-4255. Hosono Y, Niknafs YS, Prensner JR, Iyer MK, Dhanasekaran SM, Mehra R, Pitchiaya S, Tien J, Escara-Wilke J, Poliakov A, Chu SC, Saleh S, Sankar K, Su F, Guo S, Qiao Y, Freier SM, Bui HH, Cao X, Malik R, Johnson TM, Beer DG, Feng FY, Zhou W, Chinnaiyan AM. PMID: 37714137; PMCID: PMC11286225.
      View in: PubMed   Mentions: 1     Fields:    
    34. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate. J Clin Oncol. 2023 Nov 10; 41(32):5005-5014. Roy S, Romero T, Michalski JM, Feng FY, Efstathiou JA, Lawton CAF, Bolla M, Maingon P, de Reijke T, Joseph D, Ong WL, Sydes MR, Dearnaley DP, Tree AC, Carrier N, Nabid A, Souhami L, Incrocci L, Heemsbergen WD, Pos FJ, Zapatero A, Guerrero A, Alvarez A, San-Segundo CG, Maldonado X, Reiter RE, Rettig MB, Nickols NG, Steinberg ML, Valle LF, Ma TM, Farrell MJ, Neilsen BK, Juarez JE, Deng J, Vangala S, Avril N, Jia AY, Zaorsky NG, Sun Y, Spratt D, Kishan AU, Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators. PMID: 37639648; PMCID: PMC10642893.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    35. Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer. NAR Cancer. 2023 Sep; 5(3):zcad045. Zivanovic A, Miller JT, Munro SA, Knutson TP, Li Y, Passow CN, Simonaitis P, Lynch M, Oseth L, Zhao SG, Feng FY, Wikström P, Corey E, Morrissey C, Henzler C, Raphael BJ, Dehm SM. PMID: 37636316; PMCID: PMC10448862.
      View in: PubMed   Mentions: 3  
    36. The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. Cancer Res. 2023 08 15; 83(16):2763-2774. Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, Sjöström M, Chou J, Chang K, Moreno-Rodriguez T, Shrestha R, Baskin A, Zhu X, Weinstein AS, Younger N, Alumkal JJ, Beer TM, Chi KN, Evans CP, Gleave M, Lara PN, Reiter RE, Rettig MB, Witte ON, Wyatt AW, Feng FY, Small EJ, Quigley DA. PMID: 37289025; PMCID: PMC10425725.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    37. Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer. Eur Urol Oncol. 2024 Apr; 7(2):241-247. Sutera P, Shetty AC, Song Y, Hodges T, Hoang T, Rana Z, Pienta K, Feng F, Song DY, DeWeese T, Gillessen S, Sweeney C, James N, Attard G, Deek M, Tran PT. PMID: 37558543; PMCID: PMC10850431.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    38. Multi-institutional Development and External Validation of a Machine Learning Model for the Prediction of Distant Metastasis in Patients Treated by Salvage Radiotherapy for Biochemical Failure After Radical Prostatectomy. Eur Urol Focus. 2024 Jan; 10(1):66-74. Sabbagh A, Tilki D, Feng J, Huland H, Graefen M, Wiegel T, Böhmer D, Hong JC, Valdes G, Cowan JE, Cooperberg M, Feng FY, Mohammad T, Shelan M, D'Amico AV, Carroll PR, Mohamad O. PMID: 37507248.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes. Eur Urol Oncol. 2024 Apr; 7(2):222-230. Chappidi MR, Sjöström M, Greenland NY, Cowan JE, Baskin AS, Shee K, Simko JP, Chan E, Stohr BA, Washington SL, Nguyen HG, Quigley DA, Davicioni E, Feng FY, Carroll PR, Cooperberg MR. PMID: 37474400.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    40. CT-based radiomics nomogram for the preoperative prediction of microsatellite instability and clinical outcomes in colorectal cancer: a multicentre study. Clin Radiol. 2023 Oct; 78(10):e741-e751. Li M, Xu G, Cui Y, Wang M, Wang H, Xu X, Duan S, Shi J, Feng F. PMID: 37487841.
      View in: PubMed   Mentions: 1     Fields:    
    41. Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation. Eur Urol Oncol. 2024 Feb; 7(1):83-90. Dahl DM, Karrison TG, Michaelson MD, Pham HT, Wu CL, Swanson GP, Shipley WU, Vuky J, Lee RJ, Zietman AL, Souhami L, Chang BK, Deming RL, Ellerton JA, Sandler HM, Rodgers JP, Feng FY, Efstathiou JA. PMID: 37442672; PMCID: PMC10782593.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    42. The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature. Eur Urol Oncol. 2024 Feb; 7(1):27-43. Sood A, Kishan AU, Evans CP, Feng FY, Morgan TM, Murphy DG, Padhani AR, Pinto P, Van der Poel HG, Tilki D, Briganti A, Abdollah F. PMID: 37423774.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation Oncology. Semin Radiat Oncol. 2023 07; 33(3):232-242. Sutera P, Skinner H, Witek M, Mishra M, Kwok Y, Davicioni E, Feng F, Song D, Nichols E, Tran PT, Bergom C. PMID: 37331778; PMCID: PMC10446901.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    44. Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies. Eur Urol. 2023 09; 84(3):331-340. Feng F, Miladinovic B, Zhang K, Dignam JJ, Wang D, Yu M, Sandler H. PMID: 37393115; PMCID: PMC10947998.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    45. Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. NEJM Evid. 2023 Aug; 2(8):EVIDoa2300023. Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, Sandler HM, Tran PT, Rodgers JP, Esteva A, Yamashita R, Feng FY. PMID: 38320143; PMCID: PMC11195914.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    46. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels. Ann Oncol. 2023 09; 34(9):813-825. Helzer KT, Sharifi MN, Sperger JM, Shi Y, Annala M, Bootsma ML, Reese SR, Taylor A, Kaufmann KR, Krause HK, Schehr JL, Sethakorn N, Kosoff D, Kyriakopoulos C, Burkard ME, Rydzewski NR, Yu M, Harari PM, Bassetti M, Blitzer G, Floberg J, Sjöström M, Quigley DA, Dehm SM, Armstrong AJ, Beltran H, McKay RR, Feng FY, O'Regan R, Wisinski KB, Emamekhoo H, Wyatt AW, Lang JM, Zhao SG. PMID: 37330052; PMCID: PMC10527168.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    47. Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer. Nat Commun. 2023 06 09; 14(1):3357. Nguyen T, Sridaran D, Chouhan S, Weimholt C, Wilson A, Luo J, Li T, Koomen J, Fang B, Putluri N, Sreekumar A, Feng FY, Mahajan K, Mahajan NP. PMID: 37296155; PMCID: PMC10256812.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    48. Reply to V. Nardone et al. J Clin Oncol. 2023 08 10; 41(23):3959-3960. Sjöström M, Fyles A, Liu FF, McCready D, Feng FY, Speers CW, Pierce LJ, Holmberg E, Fernö M, Malmström P, Karlsson P. PMID: 37279434.
      View in: PubMed   Mentions:    Fields:    
    49. Integrative identification of non-coding regulatory regions driving metastatic prostate cancer. bioRxiv. 2023 Jun 02. Woo BJ, Moussavi-Baygi R, Karner H, Karimzadeh M, Garcia K, Joshi T, Yin K, Navickas A, Gilbert LA, Wang B, Asgharian H, Feng FY, Goodarzi H. PMID: 37398273; PMCID: PMC10312451.
      View in: PubMed   Mentions:
    50. Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial. Eur Urol. 2023 08; 84(2):156-163. Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Jones CU, Horwitz EM, Rodgers JP, Feng FY, Rosenthal SA. PMID: 37179241; PMCID: PMC10662642.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    51. Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer. Eur Urol. 2023 12; 84(6):531-535. Sutera P, Song Y, Van der Eecken K, Shetty AC, English K, Hodges T, Chang J, Fonteyne V, Rana Z, Ren L, Mendes AA, Lumen N, Delrue L, Verbeke S, De Man K, Song DY, Pienta K, Feng FY, Joniau S, Lotan T, Lane B, Kiess A, Rowe S, Pomper M, DeWeese T, Deek M, Sweeney C, Ost P, Tran PT. PMID: 37173210; PMCID: PMC10636237.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    52. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. Ann Oncol. 2023 07; 34(7):605-614. Sutera PA, Shetty AC, Hakansson A, Van der Eecken K, Song Y, Liu Y, Chang J, Fonteyne V, Mendes AA, Lumen N, Delrue L, Verbeke S, De Man K, Rana Z, Hodges T, Hamid A, Roberts N, Song DY, Pienta K, Ross AE, Feng F, Joniau S, Spratt D, Gillessen S, Attard G, James ND, Lotan T, Davicioni E, Sweeney C, Tran PT, Deek MP, Ost P. PMID: 37164128; PMCID: PMC10330666.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    53. Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2023 10 01; 117(2):370-377. Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. PMID: 37137444; PMCID: PMC10949135.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    54. Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial. Clin Cancer Res. 2023 05 01; 29(9):1783-1793. Stenmark Tullberg A, Sjöström M, Niméus E, Killander F, Chang SL, Feng FY, Speers CW, Pierce LJ, Kovács A, Lundstedt D, Holmberg E, Karlsson P. PMID: 37071498; PMCID: PMC10150244.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    55. Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. Res Sq. 2023 Apr 21. Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, NRG Prostate Cancer AI Consortium, Sandler HM, Tran PT, Rodgers JP, Esteva A, Yamashita R, Feng FY. PMID: 37131691; PMCID: PMC10153374.
      View in: PubMed   Mentions:
    56. DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations. Cancer Res. 2023 04 14; 83(8):1203-1213. Gallon J, Rodriguez-Calero A, Benjak A, Akhoundova D, Maletti S, Amstutz U, Hewer E, Genitsch V, Fleischmann A, Rushing EJ, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya AO, Bubendorf L, Moch H, Thalmann G, Feng FY, Gillessen S, Ng CKY, Rubin MA, Piscuoglio S. PMID: 36749655; PMCID: PMC10102845.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    57. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight. 2023 04 10; 8(7). Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, Low JY, Hanratty B, Ang LS, Bhatia V, Adil M, Bakbak H, Quigley DA, Schweizer MT, Hawley JE, Kollath L, True LD, Feng FY, Bander NH, Corey E, Lee JK, Morrissey C, Gulati R, Nelson PS, Haffner MC. PMID: 36821396; PMCID: PMC10132157.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    58. Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning. Nat Commun. 2023 04 08; 14(1):1968. de Jong AC, Danyi A, van Riet J, de Wit R, Sjöström M, Feng F, de Ridder J, Lolkema MP. PMID: 37031196; PMCID: PMC10082805.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    59. Radiomics model and clinical scale for the preoperative diagnosis of silent corticotroph adenomas. J Endocrinol Invest. 2023 Sep; 46(9):1843-1854. Wang H, Chang J, Zhang W, Fang Y, Li S, Fan Y, Jiang S, Yao Y, Deng K, Lu L, Bao X, Feng F, Wang R, Feng M. PMID: 37020103.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    60. Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer. Clin Cancer Res. 2023 04 03; 29(7):1232-1242. Chopra S, Trepka K, Sakhamuri S, Carretero-González A, Zhu J, Egusa E, Zhou J, Leung K, Zhao N, Hooshdaran N, Feng FY, Wells JA, Chou J, Evans MJ. PMID: 36648492; PMCID: PMC10073270.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    61. Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate Cancer. NEJM Evid. 2023 Apr; 2(4):EVIDoa2200195. Gharzai LA, Jiang R, Jaworski EM, Morales Rivera K, Dess RT, Jackson WC, Hartman HE, Mehra R, Kishan AU, Solanki AA, Schaeffer EM, Feng FY, Zaorsky NG, Berlin A, Ponsky L, Shoag J, Sun Y, Schipper MJ, Garcia J, Spratt DE. PMID: 38320030.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    62. Race-dependent association of clinical trial participation with improved outcomes for high-risk prostate cancer patients treated in the modern era. Prostate Cancer Prostatic Dis. 2023 09; 26(3):625-627. Ma TM, Feng FY, Rosenthal SA, Rettig MB, Raldow AC, Spratt DE, Xiang M, Kishan AU. PMID: 36966268.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    63. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 05; 185:178-215. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. PMID: 37003085.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    64. Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2023 04; 6(2):224-227. Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, Nickols NG, Feng FY, Nguyen PL, Nagar H, Spratt DE, Attard G, Weiner A, Weidhaas JB, Calais J, Ma TM, Davicioni E, Xiang M, Kishan AU. PMID: 36870853.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    65. Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. J Clin Oncol. 2023 05 01; 41(13):2428-2435. Tilki D, Chen MH, Wu J, Huland H, Graefen M, Mohamad O, Cowan JE, Feng FY, Carroll PR, D'Amico AV. PMID: 36857638; PMCID: PMC10150889.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    66. Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer. Eur Urol Oncol. 2023 Oct; 6(5):501-507. Sabbagh A, Washington SL, Tilki D, Hong JC, Feng J, Valdes G, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Cowan JE, Cooperberg M, Feng FY, Roach M, Trock BJ, Partin AW, D'Amico AV, Carroll PR, Mohamad O. PMID: 36868922.
      View in: PubMed   Mentions: 2     Fields:    
    67. Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med. 2023 Feb 22; 6(1):27. Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE, NRG Prostate Cancer AI Consortium, Sandler HM, Tran PT, Spratt DE, Pugh S, Feng FY, Mohamad O. PMID: 36813827; PMCID: PMC9947124.
      View in: PubMed   Mentions:
    68. Radiomics nomogram integrating intratumoural and peritumoural features to predict lymph node metastasis and prognosis in clinical stage IA non-small cell lung cancer: a two-centre study. Clin Radiol. 2023 05; 78(5):e359-e367. Chen QL, Li MM, Xue T, Peng H, Shi J, Li YY, Duan SF, Feng F. PMID: 36858926.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    69. Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial. Res Sq. 2023 Feb 08. Parry MA, Grist E, Mendes L, Dutey-Magni P, Sachdeva A, Brawley C, Murphy L, Proudfoot J, Lall S, Liu Y, Friedrich S, Ismail M, Hoyle A, Ali A, Haran A, Wingate A, Zakka L, Wetterskog D, Amos CL, Atako NB, Wang V, Rush HL, Jones RJ, Leung H, Cross WR, Gillessen S, Parker CC, Chowdhury S, STAMPEDE collaborators, Lotan T, Marafioti T, Urbanucci A, Schaeffer EM, Spratt DE, Waugh D, Powles T, Berney DM, Sydes MR, Parmar MKB, Hamid AA, Feng FY, Sweeney CJ, Davicioni E, Clarke NW, James ND, Brown LC, Attard G. PMID: 36798177; PMCID: PMC9934744.
      View in: PubMed   Mentions:
    70. New staging systems in nonmetastatic prostate cancer. Clin Adv Hematol Oncol. 2023 02; 21(2):85-87. Feng F. PMID: 36780474.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    71. Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. Eur Urol. 2024 Apr; 85(4):373-381. Mell LK, Pugh SL, Jones CU, Nelson TJ, Zakeri K, Rose BS, Zeitzer KL, Gore EM, Bahary JP, Souhami L, Michalski JM, Hartford AC, Mishra MV, Roach M, Parliament MB, Choi KN, Pisansky TM, Husain SM, Malone SC, Horwitz EM, Feng F. PMID: 36710205; PMCID: PMC10372191.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    72. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. Cancer Res. 2023 01 18; 83(2):301-315. Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Hashemi Sadraei N, Yu B, Salvati M, Bailis JM, Feng FY, Flavell RR, Aggarwal R. PMID: 36351060; PMCID: PMC10263373.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimals
    73. Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer. J Clin Oncol. 2023 03 10; 41(8):1533-1540. Sjöström M, Fyles A, Liu FF, McCready D, Shi W, Rey-McIntyre K, Chang SL, Feng FY, Speers CW, Pierce LJ, Holmberg E, Fernö M, Malmström P, Karlsson P. PMID: 36599119; PMCID: PMC10022846.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    74. Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2023 Jul 15; 116(4):770-778. Lukka HR, Deshmukh S, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M, Feng FY, Pugh SL, Sandler HM, Kachnic LA. PMID: 36592721; PMCID: PMC10619484.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    75. Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials. Int J Radiat Oncol Biol Phys. 2023 07 01; 116(3):521-529. Nguyen PL, Huang HR, Spratt DE, Davicioni E, Sandler HM, Shipley WU, Efstathiou JA, Simko JP, Pollack A, Dicker AP, Roach M, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Rabinovitch RA, Peters CA, Rodgers JP, Tran P, Feng FY. PMID: 36596347; PMCID: PMC10281690.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    76. Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126. Cancer. 2023 03 01; 129(5):685-696. McDonald AM, DeMora L, Yang ES, Hoyle JM, Lenzie A, Williams GR, Michalski JM, Yee D, Bahary JP, Den RB, Roach M, Dess R, Mishra MV, Valicenti RK, Lau HY, Marcrom SR, Souhami L, Mendez LC, Chen Y, Doncals DE, Pugh SL, Feng FY, Sandler HM. PMID: 36579470; PMCID: PMC10231027.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    77. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023 03; 83(3):267-293. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. PMID: 36494221; PMCID: PMC7614721.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    78. IL-1β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis. Cancer Res Commun. 2022 12; 2(12):1545-1557. DiNatale A, Worrede A, Iqbal W, Marchioli M, Toth A, Sjöström M, Zhu X, Corey E, Feng FY, Zhou W, Fatatis A. PMID: 36561929; PMCID: PMC9770512.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    79. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. Urol Oncol. 2023 03; 41(3):145.e7-145.e15. Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ. PMID: 36435709.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    80. The CIC-ERF co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression. Elife. 2022 Nov 16; 11. Gupta N, Song H, Wu W, Ponce RK, Lin YK, Kim JW, Small EJ, Feng FY, Huang FW, Okimoto RA. PMID: 36383412; PMCID: PMC9668335.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    81. Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance. Nat Commun. 2022 11 14; 13(1):6929. Sridaran D, Chouhan S, Mahajan K, Renganathan A, Weimholt C, Bhagwat S, Reimers M, Kim EH, Thakur MK, Saeed MA, Pachynski RK, Seeliger MA, Miller WT, Feng FY, Mahajan NP. PMID: 36376335; PMCID: PMC9663509.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    82. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. J Clin Oncol. 2023 02 20; 41(6):1307-1317. Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, Miller S, Proudfoot JA, Deek MP, Phillips R, Lotan T, Paller CJ, Marshall CH, Markowski M, Dipasquale S, Denmeade S, Carducci M, Eisenberger M, DeWeese TL, Orton M, Deville C, Davicioni E, Liauw SL, Heath EI, Greco S, Desai NB, Spratt DE, Feng F, Wang H, Beer TM, Antonarakis ES. PMID: 36367998; PMCID: PMC9940936.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    83. PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors. Mol Cancer Ther. 2022 11 03; 21(11):1722-1728. Thomas A, Fontaine SD, Diolaiti ME, Desai P, Kumar R, Takahashi N, Sciuto L, Nichols S, Ashworth A, Feng FY, Ashley GW, Nguyen M, Pommier Y, Santi DV. PMID: 35999657; PMCID: PMC10673686.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    84. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res. 2022 11 02; 82(21):3888-3902. Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. PMID: 36251389; PMCID: PMC9627125.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    85. Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2. Cancer Res. 2022 11 02; 82(21):3950-3961. O'Leary PC, Chen H, Doruk YU, Williamson T, Polacco B, McNeal AS, Shenoy T, Kale N, Carnevale J, Stevenson E, Quigley DA, Chou J, Feng FY, Swaney DL, Krogan NJ, Kim M, Diolaiti ME, Ashworth A. PMID: 36273492; PMCID: PMC9633439.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    86. Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy. JAMA Netw Open. 2022 11 01; 5(11):e2242378. Magliocco AM, Moughan J, Miyamoto DT, Simko J, Shipley WU, Gray PJ, Hagan MP, Parliament M, Tester WJ, Zietman AL, McCarthy S, Saeed-Vafa D, Xiong Y, Ayral T, Hartford AC, Patel A, Rosenthal SA, Chafe S, Greenberg R, Schwartz MA, Augspurger ME, Keech JA, Winter KA, Feng FY, Efstathiou JA. PMID: 36383379; PMCID: PMC9669810.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    87. The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. Nat Commun. 2022 10 29; 13(1):6467. Chen S, Petricca J, Ye W, Guan J, Zeng Y, Cheng N, Gong L, Shen SY, Hua JT, Crumbaker M, Fraser M, Liu S, Bratman SV, van der Kwast T, Pugh T, Joshua AM, De Carvalho DD, Chi KN, Awadalla P, Ji G, Feng F, Wyatt AW, He HH. PMID: 36309516; PMCID: PMC9617856.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    88. Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiation Therapy. Pract Radiat Oncol. 2023 Mar-Apr; 13(2):e166-e175. Quinn TJ, Chapman D, Parzen J, Wahl DR, McNamara A, Dess R, Chan J, Feng F, Jackson WC, Hamstra D. PMID: 36503624.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    89. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials. J Clin Oncol. 2023 02 01; 41(4):881-892. Ma TM, Sun Y, Malone S, Roach M, Dearnaley D, Pisansky TM, Feng FY, Sandler HM, Efstathiou JA, Syndikus I, Hall EC, Tree AC, Sydes MR, Cruickshank C, Roy S, Bolla M, Maingon P, De Reijke T, Nabid A, Carrier N, Souhami L, Zapatero A, Guerrero A, Alvarez A, Gonzalez San-Segundo C, Maldonado X, Romero T, Steinberg ML, Valle LF, Rettig MB, Nickols NG, Shoag JE, Reiter RE, Zaorsky NG, Jia AY, Garcia JA, Spratt DE, Kishan AU, Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators. PMID: 36269935; PMCID: PMC9902004.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    90. Molecular Genetics of Prostate Cancer and Role of Genomic Testing. Surg Pathol Clin. 2022 Dec; 15(4):617-628. Akhoundova D, Feng FY, Pritchard CC, Rubin MA. PMID: 36344179.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    91. Impact of radiopharmaceutical therapy (177Lu, 225Ac) microdistribution in a cancer-associated fibroblasts model. EJNMMI Phys. 2022 Sep 30; 9(1):67. Tranel J, Palm S, Graves SA, Feng FY, Hope TA. PMID: 36178531; PMCID: PMC9525486.
      View in: PubMed   Mentions: 2  
    92. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. Int J Radiat Oncol Biol Phys. 2023 03 01; 115(3):645-653. Patel SA, Ma TM, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, DeWeese TL, Tilki D, Ciezki JP, Karnes RJ, Nickols NG, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Boutros PC, Romero T, Horwitz EM, Tendulkar RD, Steinberg ML, Spratt DE, Xiang M, Kishan AU. PMID: 36179990.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    93. The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy - Authors' reply. Lancet. 2022 09 17; 400(10356):885-886. Pollack A, Karrison TG, Feng F, Sartor O, Sandler HM. PMID: 36116477.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    94. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. Nat Commun. 2022 09 15; 13(1):5345. Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, Patel RA, Haffner MC, Hu YM, Sun D, Beer TM, Foye A, Aggarwal R, Quigley DA, Youngren JF, Ryan CJ, Gleave M, Wang Y, Huang J, Coleman I, Morrissey C, Nelson PS, Evans CP, Lara P, Reiter RE, Witte O, Rettig M, Wong CK, Weinstein AS, Uzunangelov V, Stuart JM, Thomas GV, Feng FY, Small EJ, Yates JA, Xia Z, Alumkal JJ. PMID: 36109521; PMCID: PMC9477876.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    95. Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence. Cancer Discov. 2022 09 02; 12(9):2074-2097. Linder S, Hoogstraat M, Stelloo S, Eickhoff N, Schuurman K, de Barros H, Alkemade M, Bekers EM, Severson TM, Sanders J, Huang CF, Morova T, Altintas UB, Hoekman L, Kim Y, Baca SC, Sjöström M, Zaalberg A, Hintzen DC, de Jong J, Kluin RJC, de Rink I, Giambartolomei C, Seo JH, Pasaniuc B, Altelaar M, Medema RH, Feng FY, Zoubeidi A, Freedman ML, Wessels LFA, Butler LM, Lack NA, van der Poel H, Bergman AM, Zwart W. PMID: 35754340; PMCID: PMC7613567.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    96. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J Clin Oncol. 2022 10 10; 40(29):3377-3382. Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, Mishra M, Rana Z, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J, Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A, Pienta KJ, Diehn M, Bentzen SM, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, Tran PT. PMID: 36001857; PMCID: PMC10166371.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    97. [Efficacy and safety of combination therapy with chemotherapy, programmed death-1 inhibitor and anlotinib in the treatment of advanced dedifferentiated liposarcoma]. Zhonghua Yi Xue Za Zhi. 2022 Aug 23; 102(31):2428-2434. Guo X, Zhuang RY, Zhou YH, You CL, Zhang Y, Feng F, Shen ZM, Wang WS, Liu Y, Zhang HX, Tong WQ, Lu RK, Luo R. PMID: 36000371.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    98. Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN). Eur Urol. 2022 11; 82(5):487-498. Ma TM, Chu FI, Sandler H, Feng FY, Efstathiou JA, Jones CU, Roach M, Rosenthal SA, Pisansky T, Michalski JM, Bolla M, de Reijke TM, Maingon P, Neven A, Denham J, Steigler A, Joseph D, Nabid A, Souhami L, Carrier N, Incrocci L, Heemsbergen W, Pos FJ, Sydes MR, Dearnaley DP, Tree AC, Syndikus I, Hall E, Cruickshank C, Malone S, Roy S, Sun Y, Zaorsky NG, Nickols NG, Reiter RE, Rettig MB, Steinberg ML, Reddy VK, Xiang M, Romero T, Spratt DE, Kishan AU, Meta-analysis of Randomized trials in Cancer of the Prostate MARCAP Consortium investigators. PMID: 35934601.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    99. Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate. 2022 08; 82 Suppl 1:S73-S85. Sutera P, Deek MP, Van der Eecken K, Wyatt AW, Kishan AU, Molitoris JK, Ferris MJ, Siddiqui MM, Rana Z, Mishra MV, Kwok Y, Davicioni E, Spratt DE, Ost P, Feng FY, Tran PT. PMID: 35657158; PMCID: PMC9202472.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    100. [A cognitive and attitude survey of the implementation of enhanced recovery after surgery in gastrointestinal surgery in China]. Zhonghua Wei Chang Wai Ke Za Zhi. 2022 Jul 25; 25(7):621-624. Feng XY, Zhang P, Nie H, Ji G, Yang B, Feng F, Wang SQ, Ma YM, Jiang K, Zhao QC. PMID: 35844125.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    101. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature. 2022 08; 608(7921):199-208. Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, Korhonen OV, Munzur AD, Beja K, Schönlau E, Bernales CQ, Ritch E, Bacon JVW, Lack NA, Nykter M, Aggarwal R, Small EJ, Gleave ME, SU2C/PCF West Coast Prostate Cancer Dream Team, Quigley DA, Feng FY, Chi KN, Wyatt AW. PMID: 35859180.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    102. Prognostic predictors of non-small cell lung cancer treated with curative resection: the role of preoperative CT texture features, clinical features, and laboratory parameters. Clin Radiol. 2022 10; 77(10):e765-e770. Zhou L, Feng F, Yang Y, Zheng X, Yang Y. PMID: 35843728.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    103. CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clin Cancer Res. 2022 07 15; 28(14):3066-3075. Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Lim SA, Leung KK, Egusa EA, Zhu J, Zhang L, Foye A, Sriram R, Chan E, Seo Y, Feng FY, Small EJ, Chou J, Wells JA, Aggarwal R, Evans MJ. PMID: 35604681; PMCID: PMC9288514.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    104. Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601. J Clin Oncol. 2022 09 20; 40(27):3172-3179. Jackson WC, Tang M, Schipper MJ, Sandler HM, Zumsteg ZS, Efstathiou JA, Shipley WU, Seiferheld W, Lukka HR, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Hall WA, Dess RT, Lovett RD, Balogh AG, Feng FY, Spratt DE. PMID: 35737923; PMCID: PMC9514834.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    105. [Angiotensin-converting enzyme 2 particapates in ozone-induced lung inflammation and airway remodeling in mice]. Nan Fang Yi Ke Da Xue Xue Bao. 2022 Jun 20; 42(6):860-867. Wang Y, Zhang Y, Zhang L, Li M, Zhu P, Ji W, Liang R, Qiin L, Wu W, Feng F, Jin Y. PMID: 35790436; PMCID: PMC9257367.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    106. Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting. Sci Transl Med. 2022 06 15; 14(649):eabg4132. Sawant M, Mahajan K, Renganathan A, Weimholt C, Luo J, Kukshal V, Jez JM, Jeon MS, Zhang B, Li T, Fang B, Luo Y, Lawrence NJ, Lawrence HR, Feng FY, Mahajan NP. PMID: 35704598; PMCID: PMC10259236.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    107. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med. 2022 Jun 08; 5(1):71. Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE, NRG Prostate Cancer AI Consortium, Sandler HM, Tran PT, Spratt DE, Pugh S, Feng FY, Mohamad O. PMID: 35676445; PMCID: PMC9177850.
      View in: PubMed   Mentions: 20  
    108. A study on serum pro-neurotensin (PNT), furin, and zinc alpha-2-glycoprotein (ZAG) levels in patients with acromegaly. J Endocrinol Invest. 2022 Oct; 45(10):1945-1954. Ke X, Duan L, Gong F, Zhang Y, Deng K, Yao Y, Wang L, Feng F, Xing B, Pan H, Zhu H. PMID: 35670958.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    109. The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521. Int J Radiat Oncol Biol Phys. 2022 10 01; 114(2):266-274. Hall WA, Karrison TG, Rosenthal SA, Amin MB, Gomella LG, Purdy JA, Sartor AO, Michalski JM, Garzotto MG, Bergom C, Jani AB, Lawton CAF, Simko JP, Moore JK, Gore EM, Lee WR, Nguyen PL, Danielson BL, Sandler HM, Feng FY. PMID: 35675855; PMCID: PMC9444930.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    110. The Time to Evaluate the Impact of PET PSMAs on Management of Prostate Cancer Is Now. Int J Radiat Oncol Biol Phys. 2022 06 01; 113(2):254-255. Mohamad O, Feng F. PMID: 35569471.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    111. Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. JCO Clin Cancer Inform. 2022 06; 6:e2100188. Khairnar R, DeMora L, Sandler HM, Lee WR, Villalonga-Olives E, Mullins CD, Palumbo FB, Bruner DW, Shaya FT, Bentzen SM, Shah AB, Malone S, Michalski JM, Dayes IS, Seaward SA, Albert M, Currey AD, Pisansky TM, Chen Y, Horwitz EM, DeNittis AS, Feng F, Mishra MV. PMID: 35776901; PMCID: PMC9276114.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    112. Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome. JCI Insight. 2022 05 23; 7(10). Qiu X, Brown LG, Conner JL, Nguyen HM, Boufaied N, Abou Alaiwi S, Seo JH, El Zarif T, Bell C, O'Connor E, Hanratty B, Pomerantz M, Freedman ML, Brown M, Haffner MC, Nelson PS, Feng FY, Labbé DP, Long HW, Corey E. PMID: 35603787; PMCID: PMC9220831.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    113. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022 05 14; 399(10338):1886-1901. Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, Wefel JS, Martin AG, Michalski JM, Angyalfi SJ, Lukka H, Faria SL, Rodrigues GB, Beauchemin MC, Lee RJ, Seaward SA, Allen AM, Monitto DC, Seiferheld W, Sartor O, Feng F, Sandler HM. PMID: 35569466.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    114. Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer. Clin Epigenetics. 2022 05 04; 14(1):60. Severson T, Qiu X, Alshalalfa M, Sjöström M, Quigley D, Bergman A, Long H, Feng F, Freedman ML, Zwart W, Pomerantz MM. PMID: 35509021; PMCID: PMC9069737.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    115. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. Eur Urol. 2022 07; 82(1):106-114. Kishan AU, Wang X, Sun Y, Romero T, Michalski JM, Ma TM, Feng FY, Sandler HM, Bolla M, Maingon P, De Reijke T, Neven A, Steigler A, Denham JW, Joseph D, Nabid A, Carrier N, Souhami L, Sydes MR, Dearnaley DP, Syndikus I, Tree AC, Incrocci L, Heemsbergen WD, Pos FJ, Zapatero A, Efstathiou JA, Guerrero A, Alvarez A, San-Segundo CG, Maldonado X, Xiang M, Rettig MB, Reiter RE, Zaorsky NG, Ong WL, Dess RT, Steinberg ML, Nickols NG, Roy S, Garcia JA, Spratt DE, MARCAP Consortium. PMID: 35469702.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    116. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):115-141. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. PMID: 35450732.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    117. Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. Eur Urol. 2022 Jul; 82(1):e18-e19. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke ON, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. PMID: 35440417; PMCID: PMC9012951.
      View in: PubMed   Mentions:    Fields:    
    118. A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer. Mol Cancer. 2022 03 22; 21(1):82. Fletcher CE, Deng L, Orafidiya F, Yuan W, Lorentzen MPGS, Cyran OW, Varela-Carver A, Constantin TA, Leach DA, Dobbs FM, Figueiredo I, Gurel B, Parkes E, Bogdan D, Pereira RR, Zhao SG, Neeb A, Issa F, Hester J, Kudo H, Liu Y, Philippou Y, Bristow R, Knudsen K, Bryant RJ, Feng FY, Reed SH, Mills IG, de Bono J, Bevan CL. PMID: 35317841; PMCID: PMC8939142.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    119. Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial. Adv Radiat Oncol. 2022 Sep-Oct; 7(5):100941. Shee K, de la Calle CM, Chang AJ, Wong AC, Feng FY, Gottschalk AR, Carroll PR, Nguyen HG. PMID: 35847550; PMCID: PMC9280039.
      View in: PubMed   Mentions: 3  
    120. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncol. 2022 Mar 01; 8(3):e216871. Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero T. PMID: 35050303; PMCID: PMC8778608.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    121. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. Eur Urol Oncol. 2022 12; 5(6):714-718. Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. PMID: 35216942; PMCID: PMC10262920.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    122. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):6-11. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeanunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. PMID: 35393158; PMCID: PMC8849852.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    123. Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity. Mol Oncol. 2022 07; 16(13):2451-2469. Mazzu YZ, Liao Y, Nandakumar S, Sjöström M, Jehane LE, Ghale R, Govindarajan B, Gerke TA, Lee GM, Luo JH, Chinni SR, Mucci LA, Feng FY, Kantoff PW. PMID: 34792282; PMCID: PMC9251866.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    124. Selective vulnerabilities in the proteostasis network of castration-resistant prostate cancer. Cell Chem Biol. 2022 03 17; 29(3):490-501.e4. Shkedi A, Taylor IR, Echtenkamp F, Ramkumar P, Alshalalfa M, Rivera-Márquez GM, Moses MA, Shao H, Karnes RJ, Neckers L, Feng F, Kampmann M, Gestwicki JE. PMID: 35108506; PMCID: PMC8934263.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    125. Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1. Oncogene. 2022 03; 41(11):1536-1549. Melnyk JE, Steri V, Nguyen HG, Hwang YC, Gordan JD, Hann B, Feng FY, Shokat KM. PMID: 35087237; PMCID: PMC8913362.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    126. Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer. Eur Urol. 2022 05; 81(5):437-439. Di Lalla V, Kucharczyk MJ, Wyatt AW, Feng FY, Probst S, Gravis G, So J, Saad F, Niazi T. PMID: 35065838.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    127. [Prediction of platinum-based chemotherapy sensitivity for epithelial ovarian cancer by multi-sequence MRI-based radiomic nomogram]. Zhonghua Yi Xue Za Zhi. 2022 Jan 18; 102(3):201-208. Mao MM, Li HM, Shi J, Qiu QS, Feng F. PMID: 35042289.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    128. [Analysis of disease progression rate and related factors in amyotrophic lateral sclerosis patients at initial visit]. Zhonghua Yi Xue Za Zhi. 2022 Jan 18; 102(3):222-227. Zhang JH, Wang HF, Yang F, He ZQ, Feng F, Li M, Bai JM, Wang HR, Huang XS. PMID: 35042292.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    129. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol. 2022 02; 23(2):304-316. Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, Steigler A, Denham JW, Feng FY, Zapatero A, Armstrong JG, Nabid A, Carrier N, Souhami L, Dunne MT, Efstathiou JA, Sandler HM, Guerrero A, Joseph D, Maingon P, de Reijke TM, Maldonado X, Ma TM, Romero T, Wang X, Rettig MB, Reiter RE, Zaorsky NG, Steinberg ML, Nickols NG, Jia AY, Garcia JA, Spratt DE, MARCAP Consortium group. PMID: 35051385.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    130. Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. Prostate Cancer Prostatic Dis. 2022 04; 25(4):713-719. Sutera P, Van Der Eecken K, Kishan AU, Hamid A, Grist E, Attard G, Lotan T, Mendes AA, Paller CJ, Carducci MA, Ross A, Wang H, Pienta K, Feng FY, Antonarakis ES, Ost P, Song DY, Greco S, Deville C, DeWeese T, Tran PT, Deek MP. PMID: 35013522; PMCID: PMC9310084.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    131. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat Commun. 2022 01 10; 13(1):141. Song H, Weinstein HNW, Allegakoen P, Wadsworth MH, Xie J, Yang H, Castro EA, Lu KL, Stohr BA, Feng FY, Carroll PR, Wang B, Cooperberg MR, Shalek AK, Huang FW. PMID: 35013146; PMCID: PMC8748675.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCells
    132. Prediction and verification of survival in patients with non-small-cell lung cancer based on an integrated radiomics nomogram. Clin Radiol. 2022 03; 77(3):e222-e230. Li R, Peng H, Xue T, Li J, Ge Y, Wang G, Feng F. PMID: 34974912.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    133. [Mid-term efficacy of sacral nerve stimulation for the treatment of chronic constipation]. Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Dec 25; 24(12):1073-1078. He CX, Li SS, Du KL, Liu SQ, Zhang B, Feng F, Zheng JY. PMID: 34923790.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    134. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021 12 21; 12(1):7349. Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, Chakravarti D, Warfel NA, Zhou M, Bearss JJ, Gibb EA, Alshalalfa M, Karnes RJ, Small EJ, Aggarwal R, Feng F, Wang Y, Buttyan R, Zoubeidi A, Rubin M, Gleave M, Slack FJ, Davicioni E, Beltran H, Collins C, Kraft AS. PMID: 34934057; PMCID: PMC8692330.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    135. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022 06 01; 113(2):278-289. Roy S, Zaorsky NG, Bagshaw HP, Berlin A, Tree A, Turner S, Koontz B, Nguyen P, Chen R, Dess RT, Jackson WC, Kishan AU, Stish B, Nagar H, Posadas E, Tran PT, Solanki A, Shore ND, Guo G, Ponsky L, Shoag JE, Morgans AK, Garcia JA, Showalter TN, Feng FY, Spratt DE. PMID: 34923058.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    136. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN. Eur Urol. 2022 Feb; 81(2):184-192. Saad F, Small EJ, Feng FY, Graff JN, Olmos D, Hadaschik BA, Oudard S, Londhe A, Bhaumik A, Lopez-Gitlitz A, Thomas S, Mundle SD, Chowdhury S, Smith MR. PMID: 34916086.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    137. Reply to M. K. Bos et al. J Clin Oncol. 2022 02 10; 40(5):520-522. Sperger JM, Feng FY, Armstrong AJ, Zhao SG, Lang JM. PMID: 34878806.
      View in: PubMed   Mentions:    Fields:    
    138. Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis. JAMA Netw Open. 2021 12 01; 4(12):e2139769. Ma TM, Romero T, Nickols NG, Rettig MB, Garraway IP, Roach M, Michalski JM, Pisansky TM, Lee WR, Jones CU, Rosenthal SA, Wang C, Hartman H, Nguyen PL, Feng FY, Boutros PC, Saigal C, Chamie K, Jackson WC, Morgan TM, Mehra R, Salami SS, Vince R, Schaeffer EM, Mahal BA, Dess RT, Steinberg ML, Elashoff D, Sandler HM, Spratt DE, Kishan AU. PMID: 34964855; PMCID: PMC8717118.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    139. Loss of Long Noncoding RNA NXTAR in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance. Cancer Res. 2022 01 01; 82(1):155-168. Ghildiyal R, Sawant M, Renganathan A, Mahajan K, Kim EH, Luo J, Dang HX, Maher CA, Feng FY, Mahajan NP. PMID: 34740892; PMCID: PMC8732311.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimals
    140. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. JAMA Oncol. 2021 Nov 01; 7(11):1644-1652. Aggarwal R, Rydzewski NR, Zhang L, Foye A, Kim W, Helzer KT, Bakhtiar H, Chang SL, Perry MD, Gleave M, Reiter RE, Huang J, Evans CP, Alumkal JJ, Lang JM, Yu M, Quigley DA, Sjöström M, Small EJ, Feng FY, Zhao SG. PMID: 34554200; PMCID: PMC8461554.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    141. Biological data annotation via a human-augmenting AI-based labeling system. NPJ Digit Med. 2021 Oct 07; 4(1):145. van der Wal D, Jhun I, Laklouk I, Nirschl J, Richer L, Rojansky R, Theparee T, Wheeler J, Sander J, Feng F, Mohamad O, Savarese S, Socher R, Esteva A. PMID: 34620993; PMCID: PMC8497580.
      View in: PubMed   Mentions: 9  
    142. [Methylation detection of phosphatase and tensin homolog deleted on chromosome ten gene promoter in hepatocellular carcinoma samples by next-generation sequencing]. Zhonghua Yu Fang Yi Xue Za Zhi. 2021 Oct 06; 55(10):1220-1227. Jing XK, Jiang QY, Li CS, Zhang NR, Chai YT, Feng F, Li BA, Li YK. PMID: 34706508.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    143. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. J Nucl Med. 2022 Jan; 63(1):59-68. Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, Hofman M, Koontz BF, Lin DW, Morris MJ, Rowe SP, Royce TJ, Salami S, Savir-Baruch B, Srinivas S, Hope TA. PMID: 34593595; PMCID: PMC8717184.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    144. [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study]. Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Sep 25; 24(9):775-782. Zhang P, Zhang J, Zhang B, Yang WC, Hu JB, Sun XF, Zhai G, Qian HR, Li Y, Xu H, Feng F, Wu XY, Liu HL, Liu HJ, Qiu HB, Wu XJ, Zhou YB, Shen KT, Kou YW, Fu Y, Jie ZG, Zou XM, Cao H, Gao ZD, Tao KX. PMID: 34530558.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    145. Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. NPJ Genom Med. 2021 Sep 21; 6(1):76. Rydzewski NR, Peterson E, Lang JM, Yu M, Laura Chang S, Sjöström M, Bakhtiar H, Song G, Helzer KT, Bootsma ML, Chen WS, Shrestha RM, Zhang M, Quigley DA, Aggarwal R, Small EJ, Wahl DR, Feng FY, Zhao SG. PMID: 34548481; PMCID: PMC8455625.
      View in: PubMed   Mentions: 6  
    146. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol. 2021 09; 23(9):1023-1034. Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, Karaoglanoglu F, Omur ME, Kim S, Kobelev M, Kumar S, Sivak O, Bostock C, Bishop J, Hoogstraat M, Talal A, Stelloo S, van der Poel H, Bergman AM, Ahmed M, Fazli L, Huang H, Tilley W, Goodrich D, Feng FY, Gleave M, He HH, Hach F, Zwart W, Beltran H, Selth L, Zoubeidi A. PMID: 34489572; PMCID: PMC9012003.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    147. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):294-303. Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, Zietman AL, Den RB, Leibenhaut MH, Longo JM, Bahary JP, Rosenthal SA, Souhami L, Michalski JM, Hartford AC, Amin PP, Roach M, Yee D, Efstathiou JA, Rodgers JP, Feng FY, Shipley WU. PMID: 34481017; PMCID: PMC8748315.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    148. Model Selection for the Preclinical Development of New Drug-Radiotherapy Combinations. Clin Oncol (R Coll Radiol). 2021 11; 33(11):694-704. Singh J, Hatcher S, Ku AA, Ding Z, Feng FY, Sharma RA, Pfister SX. PMID: 34474951.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    149. Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genet. 2021 11; 258-259:61-68. Swami N, Hwang WL, Guo JA, Hoffman H, Abramowitz MC, Elbakouny Z, Beltran H, Chipidza F, Choueiri T, Pra AD, Huang F, Kaochar S, Kantoff P, Kim DW, Kishan AU, Kobetz E, Marinac C, Mucci LA, Muralidhar V, Pollack A, Sanford NN, Schaeffer EM, Spratt DE, Zhao SG, Rebbeck TR, Nguyen PL, Feng FY, Mahal BA, Alshalalfa M. PMID: 34551377.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    150. An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer. Nat Commun. 2021 07 29; 12(1):4601. Das R, Sjöström M, Shrestha R, Yogodzinski C, Egusa EA, Chesner LN, Chen WS, Chou J, Dang DK, Swinderman JT, Ge A, Hua JT, Kabir S, Quigley DA, Small EJ, Ashworth A, Feng FY, Gilbert LA. PMID: 34326322; PMCID: PMC8322386.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    151. Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. Prostate Cancer Prostatic Dis. 2022 04; 25(4):677-683. Vince RA, Jiang R, Qi J, Tosoian JJ, Takele R, Feng FY, Linsell S, Johnson A, Shetty S, Hurley P, Miller DC, George A, Ghani K, Sun F, Seymore M, Dess RT, Jackson WC, Schipper M, Spratt DE, Morgan TM. PMID: 34285350; PMCID: PMC8770695.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    152. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. J Clin Oncol. 2021 09 10; 39(26):2926-2937. Sperger JM, Emamekhoo H, McKay RR, Stahlfeld CN, Singh A, Chen XE, Kwak L, Gilsdorf CS, Wolfe SK, Wei XX, Silver R, Zhang Z, Morris MJ, Bubley G, Feng FY, Scher HI, Rathkopf D, Dehm SM, Choueiri TK, Halabi S, Armstrong AJ, Wyatt AW, Taplin ME, Zhao SG, Lang JM. PMID: 34197212; PMCID: PMC8425833.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    153. Treating Localized High-Risk Prostate Cancer: Do All Roads Lead to Rome? Int J Radiat Oncol Biol Phys. 2021 Jul 01; 110(3):634-635. Mohamad O, Feng F. PMID: 34089672.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    154. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2021 Jul 01; 7(7):1005-1014. Feng FY, Thomas S, Saad F, Gormley M, Yu MK, Ricci DS, Rooney B, Brookman-May S, McCarthy S, Olmos D, Chowdhury S, Hadaschik B, Liu Y, Davicioni E, Smith MR, Small EJ. PMID: 34081076; PMCID: PMC8176389.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    155. BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. Clin Cancer Res. 2021 09 01; 27(17):4923-4936. Kim DH, Sun D, Storck WK, Welker Leng K, Jenkins C, Coleman DJ, Sampson D, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman JA, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman IM, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, Small EJ, Spratt DE, Bankhead A, Rao A, Gesner EM, Attwell S, Lakhotia S, Campeau E, Yates JA, Xia Z, Alumkal JJ. PMID: 34145028; PMCID: PMC8416959.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    156. Constraints on Cosmic Strings Using Data from the Third Advanced LIGO-Virgo Observing Run. Phys Rev Lett. 2021 Jun 18; 126(24):241102. Abbott R, Abbott TD, Abraham S, Acernese F, Ackley K, Adams A, Adams C, Adhikari RX, Adya VB, Affeldt C, Agarwal D, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Akutsu T, Aleman KM, Allen G, Allocca A, Altin PA, Amato A, Anand S, Ananyeva A, Anderson SB, Anderson WG, Ando M, Angelova SV, Ansoldi S, Antelis JM, Antier S, Appert S, Arai K, Arai K, Arai Y, Araki S, Araya A, Araya MC, Areeda JS, Arène M, Aritomi N, Arnaud N, Aronson SM, Asada H, Asali Y, Ashton G, Aso Y, Aston SM, Astone P, Aubin F, Auclair P, Aufmuth P, AultONeal K, Austin C, Babak S, Badaracco F, Bader MKM, Bae S, Bae Y, Baer AM, Bagnasco S, Bai Y, Baiotti L, Baird J, Bajpai R, Ball M, Ballardin G, Ballmer SW, Bals M, Balsamo A, Baltus G, Banagiri S, Bankar D, Bankar RS, Barayoga JC, Barbieri C, Barish BC, Barker D, Barneo P, Barnum S, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Barton MA, Bartos I, Bassiri R, Basti A, Bawaj M, Bayley JC, Baylor AC, Bazzan M, Bécsy B, Bedakihale VM, Bejger M, Belahcene I, Benedetto V, Beniwal D, Benjamin MG, Bennett TF, Bentley JD, BenYaala M, Bergamin F, Berger BK, Bernuzzi S, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bhandari AV, Bhattacharjee D, Bhaumik S, Bidler J, Bilenko IA, Billingsley G, Birney R, Birnholtz O, Biscans S, Bischi M, Biscoveanu S, Bisht A, Biswas B, Bitossi M, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bobba F, Bode N, Boer M, Bogaert G, Boldrini M, Bondu F, Bonilla E, Bonnand R, Booker P, Boom BA, Bork R, Boschi V, Bose N, Bose S, Bossilkov V, Boudart V, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branch A, Branchesi M, Breschi M, Briant T, Briggs JH, Brillet A, Brinkmann M, Brockill P, Brooks AF, Brooks J, Brown DD, Brunett S, Bruno G, Bruntz R, Bryant J, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buscicchio R, Buskulic D, Cadonati L, Caesar M, Cagnoli G, Cahillane C, Cain HW, Calderón Bustillo J, Callaghan JD, Callister TA, Calloni E, Camp JB, Canepa M, Cannavacciuolo M, Cannon KC, Cao H, Cao J, Cao Z, Capocasa E, Capote E, Carapella G, Carbognani F, Carlin JB, Carney MF, Carpinelli M, Carullo G, Carver TL, Casanueva Diaz J, Casentini C, Castaldi G, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cerdá-Durán P, Cesarini E, Chaibi W, Chakravarti K, Champion B, Chan CH, Chan C, Chan CL, Chan M, Chandra K, Chanial P, Chao S, Charlton P, Chase EA, Chassande-Mottin E, Chatterjee D, Chaturvedi M, Chatziioannou K, Chen A, Chen C, Chen HY, Chen J, Chen K, Chen X, Chen YB, Chen YR, Chen Z, Cheng H, Cheong CK, Cheung HY, Chia HY, Chiadini F, Chiang CY, Chierici R, Chincarini A, Chiofalo ML, Chiummo A, Cho G, Cho HS, Choate S, Choudhary RK, Choudhary S, Christensen N, Chu H, Chu Q, Chu YK, Chua S, Chung KW, Ciani G, Ciecielag P, Cieslar M, Cifaldi M, Ciobanu AA, Ciolfi R, Cipriano F, Cirone A, Clara F, Clark EN, Clark JA, Clarke L, Clearwater P, Clesse S, Cleva F, Coccia E, Cohadon PF, Cohen DE, Cohen L, Colleoni M, Collette CG, Colpi M, Compton CM, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corezzi S, Corley KR, Cornish N, Corre D, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Cousins B, Couvares P, Covas PB, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Criswell AW, Croquette M, Crowder SG, Cudell JR, Cullen TJ, Cumming A, Cummings R, Cuoco E, Curylo M, Canton TD, Dálya G, Dana A, DaneshgaranBajastani LM, D'Angelo B, Danilishin SL, D'Antonio S, Danzmann K, Darsow-Fromm C, Dasgupta A, Datrier LEH, Dattilo V, Dave I, Davier M, Davies GS, Davis D, Daw EJ, Dean R, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Del Favero V, De Lillo F, De Lillo N, Del Pozzo W, DeMarchi LM, De Matteis F, D'Emilio V, Demos N, Dent T, Depasse A, De Pietri R, De Rosa R, De Rossi C, DeSalvo R, De Simone R, Dhurandhar S, Díaz MC, Diaz-Ortiz M, Didio NA, Dietrich T, Di Fiore L, Di Fronzo C, Di Giorgio C, et al. PMID: 34213926.
      View in: PubMed   Mentions: 3     Fields:    
    157. The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics. Mol Cancer Res. 2021 10; 19(10):1778-1791. Siefert JC, Cioni B, Muraro MJ, Alshalalfa M, Vivié J, van der Poel HG, Schoots IG, Bekers E, Feng FY, Wessels LFA, Zwart W, Bergman AM. PMID: 34131070; PMCID: PMC9398107.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    158. Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Ann Oncol. 2021 09; 32(9):1157-1166. Hamid AA, Huang HC, Wang V, Chen YH, Feng F, Den R, Attard G, Van Allen EM, Tran PT, Spratt DE, Dittamore R, Davicioni E, Liu G, DiPaola R, Carducci MA, Sweeney CJ. PMID: 34129855; PMCID: PMC8463957.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    159. Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. Clin Cancer Res. 2021 08 15; 27(16):4539-4548. Smith MR, Thomas S, Gormley M, Chowdhury S, Olmos D, Oudard S, Feng FY, Rajpurohit Y, Urtishak K, Ricci DS, Rooney B, Lopez-Gitlitz A, Yu M, Wyatt AW, Li M, Attard G, Small EJ. PMID: 34112710.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    160. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin Cancer Res. 2021 09 15; 27(18):5123-5130. Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J. PMID: 34108177; PMCID: PMC8634828.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    161. A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria? Eur J Nucl Med Mol Imaging. 2021 12; 48(13):4463-4471. Salavati A, Gencturk M, Koksel Y, Schik AN, Carroll PR, Feng FY, Rowe SP, Lawhn-Heath C, Hope TA, Froelich JW. PMID: 34091713.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    162. Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. J Clin Oncol. 2021 07 10; 39(20):2284-2293. Tilki D, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Mohamad O, Cowan JE, Feng FY, Carroll PR, Trock BJ, Partin AW, D'Amico AV. PMID: 34086480.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    163. Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Commun Biol. 2021 06 03; 4(1):670. Rayford W, Beksac AT, Alger J, Alshalalfa M, Ahmed M, Khan I, Falagario UG, Liu Y, Davicioni E, Spratt DE, Schaeffer EM, Feng FY, Mahal B, Nguyen PL, Den RB, Greenberger MD, Bradley R, Watson JM, Beamer M, Stamatakis L, Carmen DJ, Awasthi S, Hwang J, Weil R, Merisaari H, Mohamed N, Deane LA, Chakravarty D, Yadav KK, Yamoah K, Nair SS, Tewari AK. PMID: 34083737; PMCID: PMC8175556.
      View in: PubMed   Mentions: 36  Translation:Humans
    164. [Successful surgical resection of primary cardiac angiosarcoma: a case report]. Zhonghua Xin Xue Guan Bing Za Zhi. 2021 May 24; 49(5):513-515. Qu YL, Huang C, Zhu XH, Huang GC, Ma GF, Wang Y, Feng F, Xu J. PMID: 34034388.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    165. Functional mapping of androgen receptor enhancer activity. Genome Biol. 2021 05 11; 22(1):149. Huang CF, Lingadahalli S, Morova T, Ozturan D, Hu E, Yu IPL, Linder S, Hoogstraat M, Stelloo S, Sar F, van der Poel H, Altintas UB, Saffarzadeh M, Le Bihan S, McConeghy B, Gokbayrak B, Feng FY, Gleave ME, Bergman AM, Collins C, Hach F, Zwart W, Emberly E, Lack NA. PMID: 33975627; PMCID: PMC8112059.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    166. Long noncoding RNAs in cancer metastasis. Nat Rev Cancer. 2021 07; 21(7):446-460. Liu SJ, Dang HX, Lim DA, Feng FY, Maher CA. PMID: 33953369; PMCID: PMC8288800.
      View in: PubMed   Mentions: 255     Fields:    Translation:HumansAnimals
    167. Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing. JCO Precis Oncol. 2021; 5. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Kageyama R, Wells DK, Chan JM, Friedlander T, Aggarwal R, Paris PL, Feng F, Carroll PR, Witte JS. PMID: 34250416; PMCID: PMC8232833.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    168. Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. PLoS One. 2021; 16(4):e0249123. Khairnar R, Pugh SL, Sandler HM, Lee WR, Villalonga Olives E, Mullins CD, Palumbo FB, Bruner DW, Shaya FT, Bentzen SM, Shah AB, Malone SC, Michalski JM, Dayes IS, Seaward SA, Albert M, Currey AD, Pisansky TM, Chen Y, Horwitz EM, DeNittis AS, Feng FY, Mishra MV. PMID: 33852571; PMCID: PMC8046237.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    169. Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. Eur Urol. 2021 06; 79(6):717-721. Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan AU, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, Carroll PR, Schaeffer E, Feng FY. PMID: 33840559.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    170. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021 04 01; 7(4):544-552. Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efstathiou JA, Dicker AP, Todorovic T, Margrave J, Liu YS, Dabbas B, Thompson DJS, Das R, Dignam JJ, Sweeney C, Attard G, Bahary JP, Lukka HR, Hall WA, Pisansky TM, Shah AB, Pugh SL, Shipley WU, Tran PT. PMID: 33570548; PMCID: PMC7879385.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    171. Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer. Eur Urol. 2021 07; 80(1):71-81. Kumaraswamy A, Welker Leng KR, Westbrook TC, Yates JA, Zhao SG, Evans CP, Feng FY, Morgan TM, Alumkal JJ. PMID: 33785255; PMCID: PMC8547521.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    172. CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer. Nat Commun. 2021 03 19; 12(1):1781. Ahmed M, Soares F, Xia JH, Yang Y, Li J, Guo H, Su P, Tian Y, Lee HJ, Wang M, Akhtar N, Houlahan KE, Bosch A, Zhou S, Mazrooei P, Hua JT, Chen S, Petricca J, Zeng Y, Davies A, Fraser M, Quigley DA, Feng FY, Boutros PC, Lupien M, Zoubeidi A, Wang L, Walsh MJ, Wang T, Ren S, Wei GH, He HH. PMID: 33741908; PMCID: PMC7979745.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    173. Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. Cancer. 2021 06 15; 127(12):1965-1973. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS. PMID: 33690902.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    174. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. Sci Rep. 2021 03 03; 11(1):5040. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Chan JM, Friedlander T, Wyatt AW, Aggarwal R, Paris PL, Carroll PR, Feng F, Witte JS. PMID: 33658587; PMCID: PMC7930042.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    175. Circ_0061140 promotes metastasis of bladder cancer through adsorbing microRNA-1236. Eur Rev Med Pharmacol Sci. 2021 03; 25(5):2157. Feng F, Chen AP, Wang XL, Wu GL. PMID: 33755946.
      View in: PubMed   Mentions: 1     Fields:    
    176. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncol. 2021 03; 22(3):402-410. Gharzai LA, Jiang R, Wallington D, Jones G, Birer S, Jairath N, Jaworski EM, McFarlane MR, Mahal BA, Nguyen PL, Sandler H, Morgan TM, Reichert ZR, Alumkal JJ, Mehra R, Kishan AU, Fizazi K, Halabi S, Schaeffer EM, Feng FY, Elliott D, Dess RT, Jackson WC, Schipper MJ, Spratt DE. PMID: 33662287; PMCID: PMC10949134.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    177. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. Eur Urol Oncol. 2022 02; 5(1):100-103. Ma TM, Gafita A, Shabsovich D, Juarez J, Grogan TR, Thin P, Armstrong W, Sonni I, Nguyen K, Lok V, Reiter RE, Rettig MB, Steinberg ML, Kupelian PA, Yang DD, Muralidhar V, Chu C, Feng F, Savjani R, Deng J, Parikh NR, Nickols NG, Elashoff D, Czernin J, Calais J, Kishan AU. PMID: 33602654; PMCID: PMC10262977.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    178. Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow. Phys Med Biol. 2021 01 29; 66(3):035016. Tranel J, Feng FY, James SS, Hope TA. PMID: 33321484; PMCID: PMC7880907.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    179. The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair. Nat Commun. 2021 01 15; 12(1):401. Shafi AA, McNair CM, McCann JJ, Alshalalfa M, Shostak A, Severson TM, Zhu Y, Bergman A, Gordon N, Mandigo AC, Chand SN, Gallagher P, Dylgjeri E, Laufer TS, Vasilevskaya IA, Schiewer MJ, Brunner M, Feng FY, Zwart W, Knudsen KE. PMID: 33452241; PMCID: PMC7810852.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    180. The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. Eur Urol. 2021 11; 80(5):632-640. Deek MP, Van der Eecken K, Phillips R, Parikh NR, Isaacsson Velho P, Lotan TL, Kishan AU, Maurer T, GAP6 Consortium, Boutros PC, Hovens C, Abramowtiz M, Pollack A, Desai N, Stish B, Feng FY, Eisenberger M, Carducci M, Pienta KJ, Markowski M, Paller CJ, Antonarakis ES, Berlin A, Ost P, Tran PT. PMID: 33419682; PMCID: PMC10262980.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    181. Preserving Well-being in Patients With Advanced and Late Prostate Cancer. Urology. 2021 09; 155:199-209. Handley NR, Feng FY, Guise TA, D'Andrea D, Kelly WK, Gomella LG. PMID: 33373704.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    182. Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology. 2021 09; 155:165-171. Hofmann MR, Hussain M, Dehm SM, Beltran H, Wyatt AW, Halabi S, Sweeney C, Scher HI, Ryan CJ, Feng FY, Attard G, Klein E, Miyahira AK, Soule HR, Sharifi N. PMID: 33373705.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    183. Early salvage versus adjuvant therapy for treatment of prostate cancer following prostatectomy. BMJ Evid Based Med. 2021 12; 26(6):e8. Garriga M, Feng FY, Lee WR, Hong JC. PMID: 33361287.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    184. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. Clin Cancer Res. 2021 03 01; 27(5):1305-1315. Wang S, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo Y, Liu B, Flavell RR, He J. PMID: 33293372; PMCID: PMC7925362.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    185. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Eur Urol. 2022 04; 81(4):325-330. Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, Spratt DE, Den RB, Rebbeck TR, Feng F. PMID: 33303244; PMCID: PMC9838823.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    186. A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. Eur Urol. 2021 03; 79(3):374-383. Jairath NK, Dal Pra A, Vince R, Dess RT, Jackson WC, Tosoian JJ, McBride SM, Zhao SG, Berlin A, Mahal BA, Kishan AU, Den RB, Freedland SJ, Salami SS, Kaffenberger SD, Pollack A, Tran P, Mehra R, Morgan TM, Weiner AB, Mohamad O, Carroll PR, Cooperberg MR, Karnes RJ, Nguyen PL, Michalski JM, Tward JD, Feng FY, Schaeffer EM, Spratt DE. PMID: 33293078.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    187. Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. J Clin Oncol. 2021 01 10; 39(2):136-144. Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, Alumkal JJ, Michalski J, Lee WR, Pisansky TM, Feng FY, Shipley W, Sandler HM, Schipper MJ, Roach M, Sun Y, Lawton CAF. PMID: 33275486; PMCID: PMC8189640.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    188. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncol. 2020 12 01; 6(12):1912-1920. Dess RT, Suresh K, Zelefsky MJ, Freedland SJ, Mahal BA, Cooperberg MR, Davis BJ, Horwitz EM, Terris MK, Amling CL, Aronson WJ, Kane CJ, Jackson WC, Hearn JWD, Deville C, DeWeese TL, Greco S, McNutt TR, Song DY, Sun Y, Mehra R, Kaffenberger SD, Morgan TM, Nguyen PL, Feng FY, Sharma V, Tran PT, Stish BJ, Pisansky TM, Zaorsky NG, Moraes FY, Berlin A, Finelli A, Fossati N, Gandaglia G, Briganti A, Carroll PR, Karnes RJ, Kattan MW, Schipper MJ, Spratt DE. PMID: 33090219; PMCID: PMC7582232.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    189. Accelerating precision medicine in metastatic prostate cancer. Nat Cancer. 2020 11; 1(11):1041-1053. Mateo J, McKay R, Abida W, Aggarwal R, Alumkal J, Alva A, Feng F, Gao X, Graff J, Hussain M, Karzai F, Montgomery B, Oh W, Patel V, Rathkopf D, Rettig M, Schultz N, Smith M, Solit D, Sternberg C, Van Allen E, VanderWeele D, Vinson J, Soule HR, Chinnaiyan A, Small E, Simons JW, Dahut W, Miyahira AK, Beltran H. PMID: 34258585; PMCID: PMC8274325.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    190. Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. Eur Urol Open Sci. 2020 Dec; 22:34-44. Ben-Salem S, Hu Q, Liu Y, Alshalalfa M, Zhao X, Wang I, Venkadakrishnan VB, Senapati D, Kumari S, Liu D, Sboner A, Barbieri CE, Feng F, Billaud JN, Davicioni E, Liu S, Heemers HV. PMID: 33299986; PMCID: PMC7723342.
      View in: PubMed   Mentions: 4  
    191. Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial. Clin Cancer Res. 2021 02 01; 27(3):749-758. Stenmark Tullberg A, Puttonen HAJ, Sjöström M, Holmberg E, Chang SL, Feng FY, Speers C, Pierce LJ, Lundstedt D, Killander F, Niméus E, Kovács A, Karlsson P. PMID: 33148672.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    192. Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nat Commun. 2020 11 03; 11(1):5549. Cyrta J, Augspach A, De Filippo MR, Prandi D, Thienger P, Benelli M, Cooley V, Bareja R, Wilkes D, Chae SS, Cavaliere P, Dephoure N, Uldry AC, Lagache SB, Roma L, Cohen S, Jaquet M, Brandt LP, Alshalalfa M, Puca L, Sboner A, Feng F, Wang S, Beltran H, Lotan T, Spahn M, Kruithof-de Julio M, Chen Y, Ballman KV, Demichelis F, Piscuoglio S, Rubin MA. PMID: 33144576; PMCID: PMC7642293.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    193. Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. JCO Precis Oncol. 2020 Nov; 4:1228-1238. Hall WA, Fishbane N, Liu Y, Xu MJ, Davicioni E, Mahal BA, Den RB, Dess RT, Jackson WC, Wong AC, Schaeffer EM, Karnes RJ, Carroll PR, Cooperberg MR, Bismar TA, Kim HL, Klein EA, Davis JW, Ross AE, Tosoian JJ, Morgan TM, Mehra R, Salami SS, Nguyen PL, Lawton CAF, Spratt DE, Feng F. PMID: 35050780.
      View in: PubMed   Mentions: 3     Fields:    
    194. A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nat Cancer. 2020 11; 1(11):1082-1096. Arriaga JM, Panja S, Alshalalfa M, Zhao J, Zou M, Giacobbe A, Madubata CJ, Kim JY, Rodriguez A, Coleman I, Virk RK, Hibshoosh H, Ertunc O, Ozbek B, Fountain J, Jeffrey Karnes R, Luo J, Antonarakis ES, Nelson PS, Feng FY, Rubin MA, De Marzo AM, Rabadan R, Sims PA, Mitrofanova A, Abate-Shen C. PMID: 34085047; PMCID: PMC8171279.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimals
    195. Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. Radiother Oncol. 2021 01; 154:207-213. Levin-Epstein RG, Jiang NY, Wang X, Upadhyaya SK, Collins SP, Suy S, Aghdam N, Mantz C, Katz AJ, Miszczyk L, Napieralska A, Namysl-Kaletka A, Prionas N, Bagshaw H, Buyyounouski MK, Cao M, Agazaryan N, Dang A, Yuan Y, Kupelian PA, Zaorsky NG, Spratt DE, Mohamad O, Feng FY, Mahal BA, Boutros PC, Kishan AU, Juarez J, Shabsovich D, Jiang T, Kahlon S, Patel A, Patel J, Nickols NG, Steinberg ML, Fuller DB, Kishan AU. PMID: 33035622; PMCID: PMC7956167.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    196. SV-HotSpot: detection and visualization of hotspots targeted by structural variants associated with gene expression. Sci Rep. 2020 09 28; 10(1):15890. Eteleeb AM, Quigley DA, Zhao SG, Pham D, Yang R, Dehm SM, Luo J, Feng FY, Dang HX, Maher CA. PMID: 32985524; PMCID: PMC7522247.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    197. Prospects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA. Living Rev Relativ. 2020; 23(1):3. Abbott BP, Abbott R, Abbott TD, Abraham S, Acernese F, Ackley K, Adams C, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Akutsu T, Allen G, Allocca A, Aloy MA, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Ando M, Angelova SV, Antier S, Appert S, Arai K, Arai K, Arai Y, Araki S, Araya A, Araya MC, Areeda JS, Arène M, Aritomi N, Arnaud N, Arun KG, Ascenzi S, Ashton G, Aso Y, Aston SM, Astone P, Aubin F, Aufmuth P, AultONeal K, Austin C, Avendano V, Avila-Alvarez A, Babak S, Bacon P, Badaracco F, Bader MKM, Bae SW, Bae YB, Baiotti L, Bajpai R, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barnum S, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Barton MA, Bartos I, Bassiri R, Basti A, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Bejger M, Belahcene I, Bell AS, Beniwal D, Berger BK, Bergmann G, Bernuzzi S, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bidler J, Bilenko IA, Bilgili SA, Billingsley G, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, Bitossi M, Bizouard MA, Blackburn JK, Blair CD, Blair DG, Blair RM, Bloemen S, Bode N, Boer M, Boetzel Y, Bogaert G, Bondu F, Bonilla E, Bonnand R, Booker P, Boom BA, Booth CD, Bork R, Boschi V, Bose S, Bossie K, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branchesi M, Brau JE, Briant T, Briggs JH, Brighenti F, Brillet A, Brinkmann M, Brisson V, Brockill P, Brooks AF, Brown DA, Brown DD, Brunett S, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Bustillo JC, Callister TA, Calloni E, Camp JB, Campbell WA, Canepa M, Cannon K, Cannon KC, Cao H, Cao J, Capocasa E, Carbognani F, Caride S, Carney MF, Carullo G, Diaz JC, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cerdá-Durán P, Cerretani G, Cesarini E, Chaibi O, Chakravarti K, Chamberlin SJ, Chan M, Chan ML, Chao S, Charlton P, Chase EA, Chassande-Mottin E, Chatterjee D, Chaturvedi M, Chatziioannou K, Cheeseboro BD, Chen CS, Chen HY, Chen KH, Chen X, Chen Y, Chen YR, Cheng HP, Cheong CK, Chia HY, Chincarini A, Chiummo A, Cho G, Cho HS, Cho M, Christensen N, Chu HY, Chu Q, Chu YK, Chua S, Chung KW, Chung S, Ciani G, Ciobanu AA, Ciolfi R, Cipriano F, Cirone A, Clara F, Clark JA, Clearwater P, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Cohen D, Colgan R, Colleoni M, Collette CG, Collins C, Cominsky LR, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corley KR, Cornish N, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Croquette M, Crowder SG, Cullen TJ, Cumming A, Cunningham L, Cuoco E, Canton TD, Dálya G, Danilishin SL, D'Antonio S, Danzmann K, Dasgupta A, Da Silva Costa CF, Datrier LEH, Dattilo V, Dave I, Davier M, Davis D, Daw EJ, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Pozzo WD, DeMarchi LM, Demos N, Dent T, De Pietri R, Derby J, De Rosa R, De Rossi C, DeSalvo R, de Varona O, Dhurandhar S, Díaz MC, Dietrich T, Fiore LD, Giovanni MD, Girolamo TD, Lieto AD, Ding B, Pace SD, Palma ID, Renzo FD, Dmitriev A, Doctor Z, Doi K, Donovan F, Dooley KL, Doravari S, Dorrington I, Downes TP, Drago M, Driggers JC, Du Z, Ducoin JG, Dupej P, Dwyer SE, Easter PJ, Edo TB, Edwards MC, Effler A, Eguchi S, Ehrens P, Eichholz J, Eikenberry SS, Eisenmann M, Eisenstein RA, Enomoto Y, Essick RC, Estelles H, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fazio M, Fee C, Feicht J, Fejer MM, Feng F, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferreira TA, Ferrini F, Fidecaro F, Fiori I, Fiorucci D, Fishbach M, Fisher RP, et al. PMID: 33015351; PMCID: PMC7520625.
      View in: PubMed   Mentions: 8  
    198. Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clin Cancer Res. 2020 12 01; 26(23):6204-6214. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. PMID: 32967941; PMCID: PMC7710628.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    199. GW190521: A Binary Black Hole Merger with a Total Mass of 150  M_{⊙}. Phys Rev Lett. 2020 Sep 04; 125(10):101102. Abbott R, Abbott TD, Abraham S, Acernese F, Ackley K, Adams C, Adhikari RX, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aich A, Aiello L, Ain A, Ajith P, Akcay S, Allen G, Allocca A, Altin PA, Amato A, Anand S, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Ansoldi S, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arène M, Arnaud N, Aronson SM, Arun KG, Asali Y, Ascenzi S, Ashton G, Aston SM, Astone P, Aubin F, Aufmuth P, AultONeal K, Austin C, Avendano V, Babak S, Bacon P, Badaracco F, Bader MKM, Bae S, Baer AM, Baird J, Baldaccini F, Ballardin G, Ballmer SW, Bals A, Balsamo A, Baltus G, Banagiri S, Bankar D, Bankar RS, Barayoga JC, Barbieri C, Barish BC, Barker D, Barkett K, Barneo P, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Bejger M, Belahcene I, Bell AS, Beniwal D, Benjamin MG, Bentley JD, Bergamin F, Berger BK, Bergmann G, Bernuzzi S, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bhandari AV, Bidler J, Biggs E, Bilenko IA, Billingsley G, Birney R, Birnholtz O, Biscans S, Bischi M, Biscoveanu S, Bisht A, Bissenbayeva G, Bitossi M, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bobba F, Bode N, Boer M, Boetzel Y, Bogaert G, Bondu F, Bonilla E, Bonnand R, Booker P, Boom BA, Bork R, Boschi V, Bose S, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branchesi M, Brau JE, Breschi M, Briant T, Briggs JH, Brighenti F, Brillet A, Brinkmann M, Brockill P, Brooks AF, Brooks J, Brown DD, Brunett S, Bruno G, Bruntz R, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buscicchio R, Buskulic D, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callaghan JD, Callister TA, Calloni E, Camp JB, Canepa M, Cannon KC, Cao H, Cao J, Carapella G, Carbognani F, Caride S, Carney MF, Carullo G, Casanueva Diaz J, Casentini C, Castañeda J, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cerdá-Durán P, Cesarini E, Chaibi O, Chakravarti K, Chan C, Chan M, Chandra K, Chao S, Charlton P, Chase EA, Chassande-Mottin E, Chatterjee D, Chaturvedi M, Chatziioannou K, Chen HY, Chen X, Chen Y, Cheng HP, Cheong CK, Chia HY, Chiadini F, Chierici R, Chincarini A, Chiummo A, Cho G, Cho HS, Cho M, Christensen N, Chu Q, Chua S, Chung KW, Chung S, Ciani G, Ciecielag P, Cieslar M, Ciobanu AA, Ciolfi R, Cipriano F, Cirone A, Clara F, Clark JA, Clearwater P, Clesse S, Cleva F, Coccia E, Cohadon PF, Cohen D, Colleoni M, Collette CG, Collins C, Colpi M, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corezzi S, Corley KR, Cornish N, Corre D, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Croquette M, Crowder SG, Cudell JR, Cullen TJ, Cumming A, Cummings R, Cunningham L, Cuoco E, Curylo M, Canton TD, Dálya G, Dana A, Daneshgaran-Bajastani LM, D'Angelo B, Danilishin SL, D'Antonio S, Danzmann K, Darsow-Fromm C, Dasgupta A, Datrier LEH, Dattilo V, Dave I, Davier M, Davies GS, Davis D, Daw EJ, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Delfavero M, De Lillo N, Del Pozzo W, DeMarchi LM, D'Emilio V, Demos N, Dent T, De Pietri R, De Rosa R, De Rossi C, DeSalvo R, de Varona O, Dhurandhar S, Díaz MC, Diaz-Ortiz M, Dietrich T, Di Fiore L, Di Fronzo C, Di Giorgio C, Di Giovanni F, Di Giovanni M, Di Girolamo T, Di Lieto A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Divakarla AK, Dmitriev A, Doctor Z, Donovan F, Dooley KL, Doravari S, Dorrington I, Downes TP, Drago M, Driggers JC, Du Z, Ducoin JG, Dupej P, Durante O, D'Urso D, Dwyer SE, Easter PJ, Eddolls G, Edelman B, Edo TB, Edy O, Effler A, Ehrens P, Eichholz J, Eikenberry SS, Eisenmann M, Eisenstein RA, Ejlli A, Errico L, Essick RC, Estelles H, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Ewing BE, et al. PMID: 32955328.
      View in: PubMed   Mentions: 7     Fields:    
    200. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):174-185. Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efstathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, Rosenthal SA, Koontz BF, Wong AC, Nguyen PL, Hope TA, Feng F, Sandler HM, Lawton CAF. PMID: 32861817; PMCID: PMC7736505.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    201. The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells. Bioorg Med Chem. 2020 10 15; 28(20):115712. Melnyk JE, Steri V, Nguyen HG, Hann B, Feng FY, Shokat KM. PMID: 33069070.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    202. False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. Eur J Nucl Med Mol Imaging. 2021 02; 48(2):501-508. Fendler WP, Calais J, Eiber M, Simko JP, Kurhanewicz J, Santos RD, Feng FY, Reiter RE, Rettig MB, Nickols NG, Kishan AU, PSMA PET Reader Group, Slavik R, Carroll PR, Lawhn-Heath C, Herrmann K, Czernin J, Hope TA. PMID: 32808077; PMCID: PMC7835157.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    203. Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. Clin Genitourin Cancer. 2021 06; 19(3):246-254.e5. Chipidza FE, Alshalalfa M, Mahal BA, Karnes RJ, Liu Y, Davicioni E, Martin NE, Mouw KW, Feng FY, Nguyen PL, Muralidhar V. PMID: 32896505.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    204. Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making. Urology. 2020 11; 145:197-203. Lamba N, Butler S, Mahal BA, Trinh QD, Rose B, King M, Orio P, Mouw KW, Martin N, Leeman JE, Feng FY, Nguyen PL, Muralidhar V. PMID: 32763323.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    205. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2020 09 01; 26(17):4616-4624. Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ. PMID: 32727885; PMCID: PMC7484240.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    206. A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2020 10 15; 26(20):5338-5347. Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, Attwell S, Norek K, Snyder M, Bauman L, Lakhotia S, Feng FY, Small EJ, Abida W, Alumkal JJ. PMID: 32694156; PMCID: PMC7572827.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    207. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020 08; 52(8):778-789. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. PMID: 32661416; PMCID: PMC7454228.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansCells
    208. Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. Urol Oncol. 2020 12; 38(12):931.e9-931.e16. Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara PN, Thomas GV, Li P, Lui A, Small EJ, Aggarwal RR. PMID: 32624423.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    209. Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes. J Clin Med. 2020 Jun 24; 9(6). Jairath NK, Farha MW, Srinivasan S, Jairath R, Green MD, Dess RT, Jackson WC, Weiner AB, Schaeffer EM, Zhao SG, Feng FY, El Naqa I, Spratt DE. PMID: 32599760; PMCID: PMC7356642.
      View in: PubMed   Mentions: 10  
    210. [Clinical analysis of mediastinal lymph node dissection through sternotomy approach in the treatment of papillary thyroid carcinoma with mediastinal lymph node metastasis]. Zhonghua Yi Xue Za Zhi. 2020 Jun 23; 100(24):1866-1871. Shao K, Gao SG, Xue Q, Gao YS, Li J, Wang YG, Li ZS, Lei WD, Wang B, Feng FY, Lyu F, Chen XJ, Xu ZG, Liu WS, Liu SY, Wang XL, Li ZJ, Liu J, He J. PMID: 32575929.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    211. Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors. Int J Radiat Oncol Biol Phys. 2020 11 15; 108(4):936-940. Tabrizi S, Alshalalfa M, Mahal BA, Davicioni E, Liu Y, Mouw KW, Feng F, Nguyen PL, Muralidhar V. PMID: 32585335.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    212. Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020 11 15; 108(4):917-926. Parikh NR, Chang EM, Nickols NG, Rettig MB, Raldow AC, Steinberg ML, Koontz BF, Vapiwala N, Deville C, Feng FY, Spratt DE, Reiter RE, Phillips R, Ost P, Tran PT, Kishan AU. PMID: 32544574.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    213. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. PMID: 32516092; PMCID: PMC7430215.
      View in: PubMed   Mentions: 97     Fields:    Translation:Humans
    214. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. Eur Urol. 2020 09; 78(3):327-332. Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, Spratt DE, Freedland SJ, Zhao X, Li Z, Deek M, Livingstone J, Mahal BA, Nguyen PL, Feng FY, Den RB, Schaeffer EM, Lotan TL, Karnes RJ, Klein EA, Ross AE, Grogan T, Davicioni E, Elashoff D, Boutros PC, Weidhaas JB. PMID: 32461072; PMCID: PMC8954568.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    215. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proc Natl Acad Sci U S A. 2020 06 02; 117(22):12315-12323. Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z. PMID: 32424106; PMCID: PMC7275746.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    216. A Signature That May Be Predictive of Early Versus Late Recurrence After Radiation Treatment for Breast Cancer That May Inform the Biology of Early, Aggressive Recurrences. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):686-696. Speers C, Chang SL, Pesch A, Ritter C, Olsen E, Chandler B, Moubadder L, Liu M, Cameron M, Michmerhuizen A, Wilder-Romans K, Zhao SG, Nyati S, Bartelink H, Feng FY, Pierce LJ. PMID: 32434041.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    217. Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2020 May 15; 80(10):2072. Li S, Fong KW, Gritsina G, Zhang A, Zhao JC, Kim J, Sharp A, Yuan W, Aversa C, Yang XJ, Nelson PS, Feng FY, Chinnaiyan AM, de Bono JS, Morrissey C, Rettig MB, Yu J. PMID: 32414837.
      View in: PubMed   Mentions:    Fields:    
    218. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. J Clin Oncol. 2020 09 10; 38(26):3024-3031. Jackson WC, Hartman HE, Dess RT, Birer SR, Soni PD, Hearn JWD, Reichert ZR, Kishan AU, Mahal BA, Zumsteg ZS, Efstathiou JA, Kaffenberger S, Morgan TM, Mehra R, Showalter TN, Krauss DA, Nguyen PL, Schipper MJ, Feng FY, Sandler HM, Hoskin PJ, Roach M, Spratt DE. PMID: 32396488; PMCID: PMC8265327.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    219. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020 05 01; 6(5):735-743. Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, Mahal BA, Stish BJ, Zumsteg ZS, Den RB, Hall WA, Gharzai LA, Jaworski EM, Reichert ZR, Morgan TM, Mehra R, Schaeffer EM, Sartor O, Nguyen PL, Lee WR, Rosenthal SA, Michalski JM, Schipper MJ, Dignam JJ, Pisansky TM, Zietman AL, Sandler HM, Efstathiou JA, Feng FY, Shipley WU, Spratt DE. PMID: 32215583; PMCID: PMC7189892.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    220. Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions. Am Soc Clin Oncol Educ Book. 2020 May; 40:1-12. McKay RR, Feng FY, Wang AY, Wallis CJD, Moses KA. PMID: 32412803; PMCID: PMC10182417.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    221. Circ_0061140 promotes metastasis of bladder cancer through adsorbing microRNA-1236. Eur Rev Med Pharmacol Sci. 2020 05; 24(10):5310-5319. Feng F, Chen AP, Wang XL, Wu GL. PMID: 32495864.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    222. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2021 03; 24(1):81-87. Aggarwal R, Romero GR, Friedl V, Weinstein A, Foye A, Huang J, Feng F, Stuart JM, Small EJ. PMID: 32286548.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    223. Intermediate-risk Prostate Cancer: Stratification and Management. Eur Urol Oncol. 2020 06; 3(3):270-280. Preisser F, Cooperberg MR, Crook J, Feng F, Graefen M, Karakiewicz PI, Klotz L, Montironi R, Nguyen PL, D'Amico AV. PMID: 32303478.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    224. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer Prostatic Dis. 2020 12; 23(4):646-653. Tosoian JJ, Birer SR, Jeffrey Karnes R, Zhang J, Davicioni E, Klein EE, Freedland SJ, Weinmann S, Trock BJ, Dess RT, Zhao SG, Jackson WC, Yamoah K, Dal Pra A, Mahal BA, Morgan TM, Mehra R, Kaffenberger S, Salami SS, Kane C, Pollack A, Den RB, Berlin A, Schaeffer EM, Nguyen PL, Feng FY, Spratt DE. PMID: 32231245; PMCID: PMC10184170.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    225. Neddylation inactivation represses androgen receptor transcription and inhibits growth, survival and invasion of prostate cancer cells. Neoplasia. 2020 04; 22(4):192-202. Zhou X, Han S, Wilder-Romans K, Sun GY, Zhu H, Liu X, Tan M, Wang G, Feng FY, Sun Y. PMID: 32145689; PMCID: PMC7058827.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    226. Rapamycin (sirolimus) in treatment of recurrent intravenous leiomyomatosis: a case report. BJOG. 2020 05; 127(6):768-771. Zhang G, Feng F, Wang W, Zhu L. PMID: 32031317.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    227. Molecular chemisorption of N2 on IrO2(110). J Chem Phys. 2020 Feb 21; 152(7):074712. Martin R, Kim M, Lee CJ, Shariff MS, Feng F, Meyer RJ, Asthagiri A, Weaver JF. PMID: 32087661.
      View in: PubMed   Mentions:    Fields:    
    228. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. Clin Cancer Res. 2020 06 01; 26(11):2487-2496. Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, Voog EG, Bryce AH, McDermott R, Ricci F, Rowe J, Zhang J, Piulats JM, Fizazi K, Merseburger AS, Higano CS, Krieger LE, Ryan CJ, Feng FY, Simmons AD, Loehr A, Despain D, Dowson M, Green F, Watkins SP, Golsorkhi T, Chowdhury S. PMID: 32086346; PMCID: PMC8435354.
      View in: PubMed   Mentions: 167     Fields:    Translation:Humans
    229. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. Cancer Discov. 2020 03; 10(3):351-370. Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A. PMID: 32071145.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansCells
    230. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. Front Endocrinol (Lausanne). 2020; 11:35. Michmerhuizen AR, Chandler B, Olsen E, Wilder-Romans K, Moubadder L, Liu M, Pesch AM, Zhang A, Ritter C, Ward ST, Santola A, Nyati S, Rae JM, Hayes D, Feng FY, Spratt D, Wahl D, Eisner J, Pierce LJ, Speers C. PMID: 32117061; PMCID: PMC7027396.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    231. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 04; 77(4):508-547. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. PMID: 32001144.
      View in: PubMed   Mentions: 149     Fields:    Translation:Humans
    232. Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. Clin Cancer Res. 2020 04 15; 26(8):1965-1976. Li Y, Yang R, Henzler CM, Ho Y, Passow C, Auch B, Carreira S, Nava Rodrigues D, Bertan C, Hwang TH, Quigley DA, Dang HX, Morrissey C, Fraser M, Plymate SR, Maher CA, Feng FY, de Bono JS, Dehm SM. PMID: 31932493; PMCID: PMC7165042.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    233. [Awareness, treatment and control of hypertension in 640 000 adults in eastern China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Jan 10; 41(1):68-73. Yan XF, Yang JW, Bai XK, Wang HR, Feng F, Hou LL, Sun Y, Wang WJ, Li X. PMID: 32062945.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    234. Genomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer. 2020 04 01; 126(7):1407-1412. Mahal BA, Alshalalfa M, Zhao SG, Beltran H, Chen WS, Chipidza F, Davicioni E, Karnes RJ, Ku SY, Lotan TL, Muralidhar V, Rebbeck TR, Schaeffer EM, Spratt DE, Feng FY, Nguyen PL. PMID: 31905251; PMCID: PMC7332205.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    235. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Cancer. 2020 02 15; 126(4):717-724. Butler SS, Muralidhar V, Zhao SG, Sanford NN, Franco I, Fullerton ZH, Chavez J, D'Amico AV, Feng FY, Rebbeck TR, Nguyen PL, Mahal BA. PMID: 31794057.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansPHPublic Health
    236. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. Eur Urol. 2020 02; 77(2):201-208. Kishan AU, Chu FI, King CR, Seiferheld W, Spratt DE, Tran P, Wang X, Pugh SE, Sandler KA, Bolla M, Maingon P, De Reijke T, Nickols NG, Rettig M, Drakaki A, Liu ST, Reiter RE, Chang AJ, Feng FY, Sajed D, Nguyen PL, Kupelian PA, Steinberg ML, Boutros PC, Elashoff D, Collette L, Sandler HM. PMID: 31718822; PMCID: PMC7008470.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    237. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. Eur Urol. 2020 03; 77(3):333-341. Reimers MA, Yip SM, Zhang L, Cieslik M, Dhawan M, Montgomery B, Wyatt AW, Chi KN, Small EJ, Chinnaiyan AM, Alva AS, Feng FY, Chou J. PMID: 31640893; PMCID: PMC7365609.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    238. Middle Cerebral Artery Plaque Hyperintensity on T2-Weighted Vessel Wall Imaging Is Associated with Ischemic Stroke. AJNR Am J Neuroradiol. 2019 11; 40(11):1886-1892. Yu YN, Liu MW, Villablanca JP, Li ML, Xu YY, Gao S, Feng F, Liebeskind DS, Scalzo F, Xu WH. PMID: 31624115; PMCID: PMC6975098.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    239. Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer. J Clin Oncol. 2019 12 10; 37(35):3340-3349. Sjöström M, Chang SL, Fishbane N, Davicioni E, Zhao SG, Hartman L, Holmberg E, Feng FY, Speers CW, Pierce LJ, Malmström P, Fernö M, Karlsson P. PMID: 31618132; PMCID: PMC6901281.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    240. Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy. Clin Cancer Res. 2020 01 01; 26(1):171-182. Sjöström M, Chang SL, Fishbane N, Davicioni E, Hartman L, Holmberg E, Feng FY, Speers CW, Pierce LJ, Malmström P, Fernö M, Karlsson P. PMID: 31558478.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    241. Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. Radiother Oncol. 2019 12; 141:137-143. Hamstra DA, Pugh SL, Lepor H, Rosenthal SA, Pienta KJ, Gomella L, Peters C, D'Souza DP, Zeitzer KL, Jones CU, Hall WA, Horwitz E, Pisansky TM, Souhami L, Hartford AC, Dominello M, Feng F, Sandler HM. PMID: 31540746; PMCID: PMC6912855.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    242. Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. Clin Cancer Res. 2019 11 15; 25(22):6721-6730. Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, Davicioni E, Ross AE, Den RB, Nguyen PL, Feng FY, Lotan TL, Chinnaiyan AM, Schaeffer EM. PMID: 31515456; PMCID: PMC6858964.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    243. Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. Neuro Oncol. 2019 09 06; 21(9):1141-1149. Zhao SG, Yu M, Spratt DE, Chang SL, Feng FY, Kim MM, Speers CW, Carlson BL, Mladek AC, Lawrence TS, Sarkaria JN, Wahl DR. PMID: 31121035; PMCID: PMC6736132.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    244. [The correlation of functional connectivity and structural connectivity between hippocampus and thalamus in Alzheimer's disease and amnestic mild cognitive impairment]. Zhonghua Nei Ke Za Zhi. 2019 Sep 01; 58(9):662-667. Feng F, Zhou B, Wang L, Yao HX, Guo YE, An NY, Wang LN, Zhang X. PMID: 31461817.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    245. Author Correction: Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms. Nat Commun. 2019 Aug 28; 10(1):3948. Emami NC, Kachuri L, Meyers TJ, Das R, Hoffman JD, Hoffmann TJ, Hu D, Shan J, Feng FY, Ziv E, Van Den Eeden SK, Witte JS. PMID: 31462633; PMCID: PMC6713745.
      View in: PubMed   Mentions:    Fields:    
    246. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis. 2020 03; 23(1):136-143. Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR. PMID: 31455846; PMCID: PMC8076042.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    247. Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms. Nat Commun. 2019 07 15; 10(1):3107. Emami NC, Kachuri L, Meyers TJ, Das R, Hoffman JD, Hoffmann TJ, Hu D, Shan J, Feng FY, Ziv E, Van Den Eeden SK, Witte JS. PMID: 31308362; PMCID: PMC6629701.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    248. DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. Clin Cancer Res. 2019 09 15; 25(18):5608-5622. Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley DA, Rathkopf DE, He HH, Speers C, Spratt DE, Gilbert LA, Ashworth A, Chinnaiyan AM, Raj GV, Knudsen KE, Feng FY. PMID: 31266829; PMCID: PMC6744969.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    249. Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies. Clin Cancer Res. 2019 09 15; 25(18):5623-5637. Dylgjeri E, McNair C, Goodwin JF, Raymon HK, McCue PA, Shafi AA, Leiby BE, de Leeuw R, Kothari V, McCann JJ, Mandigo AC, Chand SN, Schiewer MJ, Brand LJ, Vasilevskaya I, Gordon N, Laufer TS, Gomella LG, Lallas CD, Trabulsi EJ, Feng FY, Filvaroff EH, Hege K, Rathkopf D, Knudsen KE. PMID: 31266833; PMCID: PMC6744985.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    250. Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019 11 01; 105(3):621-627. Muralidhar V, Zhang J, Wang Q, Mahal BA, Butler SS, Spratt DE, Davicioni E, Sartor O, Feng FY, Mouw KW, Nguyen PL. PMID: 31271825.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    251. Reply to J.B. Aragon-Ching. J Clin Oncol. 2019 09 01; 37(25):2297-2298. Rosenthal SA, Hu C, Sartor O, Feng FY, Sandler HM. PMID: 31260645.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    252. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncol. 2019 07 01; 5(7):975-983. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE. PMID: 31120534; PMCID: PMC6547116.
      View in: PubMed   Mentions: 162     Fields:    Translation:HumansCTClinical Trials
    253. Author Reply. Urology. 2019 07; 129:163-164. Boreta L, Gadzinski AJ, Hope TA, Feng FY. PMID: 31234998.
      View in: PubMed   Mentions: 1     Fields:    
    254. Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer. 2019 10 01; 125(19):3338-3346. Mahal AR, Butler S, Franco I, Muralidhar V, Larios D, Pike LRG, Zhao SG, Sanford NN, Dess RT, Feng FY, D'Amico AV, Spratt DE, Yu JB, Nguyen PL, Rebbeck TR, Mahal BA. PMID: 31251398.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    255. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature. 2019 07; 571(7765):413-418. Parolia A, Cieslik M, Chu SC, Xiao L, Ouchi T, Zhang Y, Wang X, Vats P, Cao X, Pitchiaya S, Su F, Wang R, Feng FY, Wu YM, Lonigro RJ, Robinson DR, Chinnaiyan AM. PMID: 31243372; PMCID: PMC6661908.
      View in: PubMed   Mentions: 124     Fields:    Translation:HumansCells
    256. Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. Eur Urol Oncol. 2019 07; 2(4):405-412. Alshalalfa M, Nguyen PL, Beltran H, Chen WS, Davicioni E, Zhao SG, Rebbeck TR, Schaeffer EM, Lotan TL, Feng FY, Mahal BA. PMID: 31164324; PMCID: PMC7597937.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    257. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Jun 01; 5(6):856-863. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. PMID: 30920593; PMCID: PMC6567829.
      View in: PubMed   Mentions: 248     Fields:    Translation:HumansCTClinical Trials
    258. Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer. JCO Precis Oncol. 2019; 3. Salami SS, Singhal U, Spratt DE, Palapattu GS, Hollenbeck BK, Schonhoft JD, Graf R, Louw J, Jendrisak A, Dugan L, Wang Y, Tomlins SA, Dittamore R, Feng FY, Morgan TM. PMID: 32832835; PMCID: PMC7440257.
      View in: PubMed   Mentions: 17     Fields:    
    259. Active Surveillance for Low-Risk Prostate Cancer in Black Patients. N Engl J Med. 2019 05 23; 380(21):2070-2072. Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezolosky M, Vastola M, Zhao SG, D'Amico AV, Dess RT, Feng FY, King MT, Mouw KW, Spratt DE, Trinh QD, Nguyen PL, Rebbeck TR, Mahal BA. PMID: 31116925; PMCID: PMC7374756.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    260. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol. 2019 Sep; 76(3):268-272. Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF. PMID: 31128968.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    261. Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers. Mol Cancer Res. 2019 08; 17(8):1652-1664. Goswami MT, VanDenBerg KR, Han S, Wang LL, Singh B, Weiss T, Barlow M, Kamberov S, Wilder-Romans K, Rhodes DR, Feng FY, Tomlins SA. PMID: 31110156; PMCID: PMC6679750.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    262. The current state of randomized clinical trial evidence for prostate brachytherapy. Urol Oncol. 2019 09; 37(9):599-610. Dess RT, Soni PD, Jackson WC, Berlin A, Cox BW, Jolly S, Efstathiou JA, Feng FY, Kishan AU, Stish BJ, Pisansky TM, Spratt DE. PMID: 31060795.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    263. Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer. AJR Am J Roentgenol. 2019 08; 213(2):266-274. Lawhn-Heath C, Flavell RR, Behr SC, Yohannan T, Greene KL, Feng F, Carroll PR, Hope TA. PMID: 31039025.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    264. Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clin Cancer Res. 2019 Jul 15; 25(14):4290-4299. Chen WS, Alshalalfa M, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA, Knudsen KE, Small EJ, Nguyen PL, Feng FY. PMID: 31010837; PMCID: PMC7883384.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    265. [Analysis of spatial-temporal distribution of pesticide poisoning in Quzhou, 2013-2017]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2019 Apr 20; 37(4):269-272. Zheng XW, Nie Z, Zheng Z, Liu SF, Feng F. PMID: 31177692.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    266. A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. Theranostics. 2019; 9(10):2812-2826. Jan YJ, Yoon J, Chen JF, Teng PC, Yao N, Cheng S, Lozano A, Chu GCY, Chung H, Lu YT, Chen PJ, Wang JJ, Lee YT, Kim M, Zhu Y, Knudsen BS, Feng FY, Garraway IP, Gao AC, Chung LWK, Freeman MR, You S, Tseng HR, Posadas EM. PMID: 31244925; PMCID: PMC6568173.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    267. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol Biol Phys. 2019 07 15; 104(4):778-789. Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, Gharzai LA, Jaworski EM, Mehra R, Hearn JWD, Morgan TM, Salami SS, Cooperberg MR, Mahal BA, Soni PD, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, Spratt DE. PMID: 30959121; PMCID: PMC6770993.
      View in: PubMed   Mentions: 139     Fields:    Translation:Humans
    268. Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2019 05 15; 79(10):2580-2592. Li S, Fong KW, Gritsina G, Zhang A, Zhao JC, Kim J, Sharp A, Yuan W, Aversa C, Yang XJ, Nelson PS, Feng FY, Chinnaiyan AM, de Bono JS, Morrissey C, Rettig MB, Yu J. PMID: 30952632; PMCID: PMC6522281.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansAnimalsCells
    269. Lethal clues to cancer-cell vulnerability. Nature. 2019 04; 568(7753):463-464. Feng FY, Gilbert LA. PMID: 31000834.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    270. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 11; 76(5):562-571. Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ, West Coast Prostate Cancer Dream Team. PMID: 30928160; PMCID: PMC6764911.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    271. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Mol Cancer Res. 2019 06; 17(6):1235-1240. Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ. PMID: 30918106; PMCID: PMC6548614.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    272. Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy. Urology. 2019 07; 129:165-171. Boreta L, Gadzinski AJ, Wu SY, Xu M, Greene K, Quanstrom K, Nguyen HG, Carroll PR, Hope TA, Feng FY. PMID: 30928607.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    273. A C-type lectin with a single carbohydrate-recognition domain involved in the innate immune response of Tribolium castaneum. Insect Mol Biol. 2019 10; 28(5):649-661. Bi J, Feng F, Li J, Mao J, Ning M, Song X, Xie J, Tang J, Li B. PMID: 30843264.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    274. A Tumor-Agnostic NTRK (TRK) Inhibitor. Cell. 2019 03 21; 177(1):8. Huang FW, Feng FY. PMID: 30901551.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    275. Comparison of Population-Based Observational Studies With Randomized Trials in Oncology. J Clin Oncol. 2019 05 10; 37(14):1209-1216. Soni PD, Hartman HE, Dess RT, Abugharib A, Allen SG, Feng FY, Zietman AL, Jagsi R, Schipper MJ, Spratt DE. PMID: 30897037; PMCID: PMC7186578.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    276. Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset. Eur Urol. 2019 09; 76(3):338-339. Knudsen KE, Feng FY. PMID: 30885533.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    277. Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. J Clin Oncol. 2019 05 10; 37(14):1159-1168. Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM. PMID: 30860948; PMCID: PMC6506419.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    278. [The correlation of ganglion cell layer thickness with visual field defect in non-functional pituitary adenoma with chiasm compression]. Zhonghua Yan Ke Za Zhi. 2019 Mar 11; 55(3):186-194. Zhang X, Ma J, Wang YH, Gan LY, Li L, Wang XQ, Li DH, Xing B, Feng M, Zhu HJ, Lu L, Feng F, You H, Zhang ZH, Zhong Y. PMID: 30841685.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    279. The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program. Mol Oncol. 2019 05; 13(5):1121-1136. Parolia A, Venalainen E, Xue H, Mather R, Lin D, Wu R, Pucci P, Rogalski J, Evans JR, Feng F, Collins CC, Wang Y, Crea F. PMID: 30776192; PMCID: PMC6487714.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    280. AUTHOR REPLY. Urology. 2019 03; 125:161-162. Wu SY, Feng FY, Hope TA. PMID: 30798967.
      View in: PubMed   Mentions:    Fields:    
    281. Altered exosomal miR-181d and miR-30a related to the pathogenesis of CVB3 induced myocarditis by targeting SOCS3. Eur Rev Med Pharmacol Sci. 2019 Mar; 23(5):2208-2215. Fan KL, Li MF, Cui F, Feng F, Kong L, Zhang FH, Hao H, Yin MX, Liu Y. PMID: 30915768.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    282. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J Natl Cancer Inst. 2019 03 01; 111(3):301-310. Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY. PMID: 30321406.
      View in: PubMed   Mentions: 104     Fields:    Translation:Humans
    283. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):531-538. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. PMID: 30804427; PMCID: PMC6853839.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    284. "Lincing" the Y Chromosome to Prostate Cancer: TTTY15 Takes Center Stage. Eur Urol. 2019 09; 76(3):327-328. Prensner JR, Feng FY. PMID: 30799189.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    285. Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer. Eur Urol Focus. 2019 03; 5(2):168-170. Vicier C, Feng FY, Fizazi K. PMID: 30745118.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    286. Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell. 2019 02 07; 176(4):831-843.e22. Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, Volik S, Lapuk A, Chua MLK, Heisler LE, Foucal A, Fox NS, Fraser M, Bhandari V, Shiah YJ, Guan J, Li J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Liu S, Feng F, Wu X, Shao YW, Komor MA, Sahinalp C, Collins C, Hoogstrate Y, de Jong M, Fijneman RJA, Fei T, Jenster G, van der Kwast T, Bristow RG, Boutros PC, He HH. PMID: 30735634.
      View in: PubMed   Mentions: 218     Fields:    Translation:HumansCells
    287. Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models. JAMA Netw Open. 2019 02 01; 2(2):e187765. Beesley LJ, Morgan TM, Spratt DE, Singhal U, Feng FY, Furgal AC, Jackson WC, Daignault S, Taylor JMG. PMID: 30707231; PMCID: PMC6484613.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    288. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. Eur Urol. 2019 07; 76(1):59-68. Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, da Costa JB, du Plessis M, Wang NQ, Davicioni E, Feng FY, Seiler R, Black PC, Shipley WU, Miyamoto DT. PMID: 30712971; PMCID: PMC6571058.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCells
    289. International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy. J Urol. 2019 02; 201(2):284-291. Berlin A, Moraes FY, Sanmamed N, Glicksman R, Koven A, Espin-Garcia O, Leite ETT, Silva JLF, Gadia R, Nesbitt M, Catton CN, Kaffenberger S, Salami SS, Morgan TM, Hearn JWD, Jackson WC, Mehra R, Chung P, Fleshner NE, Zumsteg ZS, Dess RT, Feng FY, Finelli A, Spratt DE. PMID: 30153435.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    290. Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. Eur Urol. 2019 06; 75(6):1038-1040. Mahal BA, Alshalalfa M, Spratt DE, Davicioni E, Zhao SG, Feng FY, Rebbeck TR, Nguyen PL, Huang FW. PMID: 30683576.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    291. ONECUT2 is a driver of neuroendocrine prostate cancer. Nat Commun. 2019 01 17; 10(1):278. Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH. PMID: 30655535; PMCID: PMC6336817.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansAnimalsCells
    292. Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. Eur Urol Oncol. 2019 11; 2(6):685-690. Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, Boreta L, Spratt DE, Behr SC, Nguyen HG, Cooperberg MR, Davicioni E, Roach M, Hope TA, Carroll PR, Feng FY. PMID: 31411984.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    293. What Is Oligometastatic Prostate Cancer? Eur Urol Focus. 2019 03; 5(2):159-161. Fraser M, Koontz B, Emmenegger U, De Meerleer G, Khoo V, Feng F, Corcoran NM, Hovens CM, Tran PT, Ost P, Boutros PC, GAP6 Consortium. PMID: 30642810.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    294. Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer. Urology. 2019 03; 125:154-162. Wu SY, Boreta L, Shinohara K, Nguyen H, Gottschalk AR, Hsu IC, Roach M, Westphalen AC, Feng FY, Carroll PR, Chang AJ, Hope TA. PMID: 30580002.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    295. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clin Cancer Res. 2019 04 15; 25(8):2450-2457. Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, Feng FY. PMID: 30573691.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    296. Reply to A. Dalla Volta et al. J Clin Oncol. 2019 02 01; 37(4):351-352. Aggarwal R, Huang J, Alumkal J, Feng FY, Zhang L, Stuart JM, Small EJ. PMID: 30557523.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    297. Search for Subsolar-Mass Ultracompact Binaries in Advanced LIGO's First Observing Run. Phys Rev Lett. 2018 Dec 07; 121(23):231103. Abbott BP, Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Agarwal B, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allen G, Allocca A, Aloy MA, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arène M, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Atallah DV, Aubin F, Aufmuth P, Aulbert C, AultONeal K, Austin C, Avila-Alvarez A, Babak S, Bacon P, Badaracco F, Bader MKM, Bae S, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barnum S, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Beer C, Bejger M, Belahcene I, Bell AS, Beniwal D, Bensch M, Berger BK, Bergmann G, Bernuzzi S, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhandare R, Bilenko IA, Bilgili SA, Billingsley G, Billman CR, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, Bitossi M, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Bode N, Boer M, Boetzel Y, Bogaert G, Bohe A, Bondu F, Bonilla E, Bonnand R, Booker P, Boom BA, Booth CD, Bork R, Boschi V, Bose S, Bossie K, Bossilkov V, Bosveld J, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branchesi M, Brau JE, Briant T, Brighenti F, Brillet A, Brinkmann M, Brisson V, Brockill P, Brooks AF, Brown DD, Brunett S, Buchanan CC, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister TA, Calloni E, Camp JB, Canepa M, Canizares P, Cannon KC, Cao H, Cao J, Capano CD, Capocasa E, Carbognani F, Caride S, Carney MF, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda CB, Cerdá-Durán P, Cerretani G, Cesarini E, Chaibi O, Chamberlin SJ, Chan M, Chao S, Charlton P, Chase E, Chassande-Mottin E, Chatterjee D, Cheeseboro BD, Chen HY, Chen X, Chen Y, Cheng HP, Chia HY, Chincarini A, Chiummo A, Chmiel T, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua AJK, Chua S, Chung KW, Chung S, Ciani G, Ciobanu AA, Ciolfi R, Cipriano F, Cirelli CE, Cirone A, Clara F, Clark JA, Clearwater P, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Cohen D, Colla A, Collette CG, Collins C, Cominsky LR, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corley KR, Cornish N, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Crowder SG, Cullen TJ, Cumming A, Cunningham L, Cuoco E, Canton TD, Dálya G, Danilishin SL, D'Antonio S, Danzmann K, Dasgupta A, Da Silva Costa CF, Dattilo V, Dave I, Davier M, Davis D, Daw EJ, Day B, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Demos N, Denker T, Dent T, De Pietri R, Derby J, Dergachev V, De Rosa R, De Rossi C, DeSalvo R, Deutsch AS, de Varona O, Dhurandhar S, Díaz MC, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Dmitriev A, Doctor Z, Dolique V, Donovan F, Dooley KL, Doravari S, Dorrington I, Dovale Álvarez M, Downes TP, Drago M, Dreissigacker C, Driggers JC, Du Z, Dupej P, Dwyer SE, Easter PJ, Edo TB, Edwards MC, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Eisenmann M, Eisenstein RA, Essick RC, Estelles H, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fee C, Fehrmann H, Feicht J, Fejer MM, Feng F, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fishner JM, Fitz-Axen M, Flaminio R, Fletcher M, Fong H, et al. PMID: 30576173.
      View in: PubMed   Mentions: 4     Fields:    
    298. PARP-1 regulates DNA repair factor availability. EMBO Mol Med. 2018 12; 10(12). Schiewer MJ, Mandigo AC, Gordon N, Huang F, Gaur S, de Leeuw R, Zhao SG, Evans J, Han S, Parsons T, Birbe R, McCue P, McNair C, Chand SN, Cendon-Florez Y, Gallagher P, McCann JJ, Poudel Neupane N, Shafi AA, Dylgjeri E, Brand LJ, Visakorpi T, Raj GV, Lallas CD, Trabulsi EJ, Gomella LG, Dicker AP, Kelly WK, Leiby BE, Knudsen B, Feng FY, Knudsen KE. PMID: 30467127; PMCID: PMC6284389.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    299. Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. Lancet Oncol. 2018 12; 19(12):e683-e695. Miyamoto DT, Mouw KW, Feng FY, Shipley WU, Efstathiou JA. PMID: 30507435.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimals
    300. Integrative epigenetic taxonomy of primary prostate cancer. Nat Commun. 2018 11 21; 9(1):4900. Stelloo S, Nevedomskaya E, Kim Y, Schuurman K, Valle-Encinas E, Lobo J, Krijgsman O, Peeper DS, Chang SL, Feng FY, Wessels LFA, Henrique R, Jerónimo C, Bergman AM, Zwart W. PMID: 30464211; PMCID: PMC6249266.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    301. Long non-coding RNAs in prostate cancer: Biological and clinical implications. Mol Cell Endocrinol. 2019 01 15; 480:142-152. Das R, Feng FY, Selth LA. PMID: 30391670.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    302. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. Eur Urol. 2019 01; 75(1):35-41. Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL. PMID: 30554605.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    303. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 10 18; 175(3):889. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30340047.
      View in: PubMed   Mentions: 66     Fields:    
    304. [Tauopathy: the gradually concerned neurodegenerative diseases]. Zhonghua Nei Ke Za Zhi. 2018 Oct 01; 57(10):700-701. Wang LN, Zhu MW, Feng F. PMID: 30293328.
      View in: PubMed   Mentions:    Fields:    
    305. [The efficacy of cognitive behavioral therapy in insomnic patients with or without comorbidities: a pilot study]. Zhonghua Nei Ke Za Zhi. 2018 Oct 01; 57(10):731-737. Wu YT, Wang J, Chen YW, Guo W, Wu EL, Tang CR, Feng F, Feng YS. PMID: 30293333.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    306. [Advances in globular glial tauopathies]. Zhonghua Nei Ke Za Zhi. 2018 Oct 01; 57(10):763-765. Feng F, Zhang X, Wang LN. PMID: 30293341.
      View in: PubMed   Mentions:    Fields:    
    307. Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. Eur Urol Oncol. 2018 09; 1(4):276-282. Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumsteg ZS, Hannan R, Hollenbeck BK, George A, Kaffenberger SD, Salami SS, Hearn JWD, Morgan TM, Mehra R, Schipper M, Feng FY, Desai NB, Spratt DE. PMID: 31100248.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    308. MechRNA: prediction of lncRNA mechanisms from RNA-RNA and RNA-protein interactions. Bioinformatics. 2018 09 15; 34(18):3101-3110. Gawronski AR, Uhl M, Zhang Y, Lin YY, Niknafs YS, Ramnarine VR, Malik R, Feng F, Chinnaiyan AM, Collins CC, Sahinalp SC, Backofen R. PMID: 29617966; PMCID: PMC6137976.
      View in: PubMed   Mentions: 28     Fields:    Translation:Cells
    309. [Value of MRI in the pre-operative diagnosis and classification of oblique vaginal septum syndrome]. Zhonghua Fu Chan Ke Za Zhi. 2018 Aug 25; 53(8):534-539. Wang Y, Lin Q, Sun ZJ, Jiang B, Hou B, Lu JJ, Zhu L, Feng F, Jin ZY, Lang JH. PMID: 30138963.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    310. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer. J Natl Compr Canc Netw. 2018 08; 16(8):933-937. Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ. PMID: 30099369.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    311. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 07 26; 174(3):758-769.e9. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30033370; PMCID: PMC6425931.
      View in: PubMed   Mentions: 283     Fields:    Translation:HumansCells
    312. Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19. Cell. 2018 07 26; 174(3):564-575.e18. Hua JT, Ahmed M, Guo H, Zhang Y, Chen S, Soares F, Lu J, Zhou S, Wang M, Li H, Larson NB, McDonnell SK, Patel PS, Liang Y, Yao CQ, van der Kwast T, Lupien M, Feng FY, Zoubeidi A, Tsao MS, Thibodeau SN, Boutros PC, He HH. PMID: 30033362.
      View in: PubMed   Mentions: 166     Fields:    Translation:HumansCells
    313. Re: Amar U. Kishan, Rahul D. Tendulkar, Phuoc T. Tran, et al. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Adenocarcinoma. Eur Urol Oncol. In press: Primum Non Nocere: Adding Hormone Therapy to Early Salvage Radiotherapy Makes the Physician Feel Better, But Does It Help the Patient? Eur Urol Oncol. 2018 09; 1(4):323-324. Spratt DE, Feng FY. PMID: 31100255.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    314. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018 08 20; 36(24):2492-2503. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. PMID: 29985747; PMCID: PMC6366813.
      View in: PubMed   Mentions: 322     Fields:    Translation:HumansCellsCTClinical Trials
    315. [Resting-state functional MRI studies of amyotrophic lateral sclerosis patients with various levels of cognitive impairment]. Zhonghua Yi Xue Za Zhi. 2018 Jul 03; 98(25):2002-2006. Shen DC, Hou B, Cui B, Li XL, Peng P, Tai HF, Zhang K, Liu SW, Fu HH, Liu MS, Feng F, Cui LY. PMID: 29996600.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    316. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell. 2018 06 14; 173(7):1770-1782.e14. Wu YM, Cieslik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N, Heath EI, Chou J, Feng FY, Nelson PS, de Bono JS, Zou W, Montgomery B, Alva A, PCF/SU2C International Prostate Cancer Dream Team, Robinson DR, Chinnaiyan AM. PMID: 29906450; PMCID: PMC6084431.
      View in: PubMed   Mentions: 242     Fields:    Translation:HumansCells
    317. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins. Cancer Res. 2018 08 15; 78(16):4760-4773. Gollavilli PN, Pawar A, Wilder-Romans K, Natesan R, Engelke CG, Dommeti VL, Krishnamurthy PM, Nallasivam A, Apel IJ, Xu T, Qin ZS, Feng FY, Asangani IA. PMID: 29898995.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    318. Genomic biomarkers in prostate cancer. Transl Androl Urol. 2018 Jun; 7(3):459-471. Kornberg Z, Cooperberg MR, Spratt DE, Feng FY. PMID: 30050804; PMCID: PMC6043739.
      View in: PubMed   Mentions: 17  
    319. Effect of matrine on reducing damage to bovine mammary epithelial cells induced by Staphylococcus aureus alpha-hemolysin. Pol J Vet Sci. 2018 Jun; 21(2):409-413. Feng F, Wa MM, Luo HX, Guan CP, Zhou XZ. PMID: 30450884.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    320. The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. Eur Urol. 2018 10; 74(4):444-452. Cooperberg MR, Erho N, Chan JM, Feng FY, Fishbane N, Zhao SG, Simko JP, Cowan JE, Lehrer J, Alshalalfa M, Kolisnik T, Chelliserry J, Margrave J, Aranes M, Plessis MD, Buerki C, Tenggara I, Davicioni E, Carroll PR. PMID: 29853306; PMCID: PMC6586429.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    321. Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nat Genet. 2018 06; 50(6):814-824. Zhang Y, Pitchiaya S, Cieslik M, Niknafs YS, Tien JC, Hosono Y, Iyer MK, Yazdani S, Subramaniam S, Shukla SK, Jiang X, Wang L, Liu TY, Uhl M, Gawronski AR, Qiao Y, Xiao L, Dhanasekaran SM, Juckette KM, Kunju LP, Cao X, Patel U, Batish M, Shukla GC, Paulsen MT, Ljungman M, Jiang H, Mehra R, Backofen R, Sahinalp CS, Freier SM, Watt AT, Guo S, Wei JT, Feng FY, Malik R, Chinnaiyan AM. PMID: 29808028; PMCID: PMC5980762.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansCells
    322. Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. Clin Cancer Res. 2018 08 15; 24(16):3908-3916. Karnes RJ, Sharma V, Choeurng V, Ashab HA, Erho N, Alshalalfa M, Trock B, Ross A, Yousefi K, Tsai H, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, Spratt DE, Abdollah F, Jenkins RB, Klein EA, Nguyen PL, Dicker AP, Den RB, Davicioni E, Feng FY, Lotan TL, Schaeffer EM. PMID: 29760221; PMCID: PMC6512950.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    323. Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways. Ann Transl Med. 2018 May; 6(9):161. Kornberg Z, Chou J, Feng FY, Ryan CJ. PMID: 29911109; PMCID: PMC5985268.
      View in: PubMed   Mentions: 6  
    324. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. Ann Oncol. 2018 05 01; 29(5):1329-1330. Liu C, Wang L, Zhuang J, Liu L, Zhou C, Feng F, Sun C. PMID: 29788163.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    325. Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. Clin Cancer Res. 2018 08 01; 24(15):3500-3509. Okunieff P, Casey-Sawicki K, Lockney NA, Hoppe BS, Enderling H, Pinnix C, Welsh J, Krishnan S, Yothers G, Brown M, Knox S, Bristow R, Spellman P, Mitin T, Nabavizadeh N, Jaboin J, Manning HC, Feng F, Galbraith S, Solanki AA, Harkenrider MM, Tuli R, Decker RH, Finkelstein SE, Hsu CC, Ha CS, Jagsi R, Shumway D, Daly M, Wang TJC, Fitzgerald TJ, Laurie F, Marshall DT, Raben D, Constine L, Thomas CR, Kachnic LA. PMID: 29661779.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    326. Live to SABR Another Day? Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1097. Tran PT, Feng F, Ost P. PMID: 29722652; PMCID: PMC6330048.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    327. Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation. Cell Rep. 2018 03 27; 22(13):3672-3683. Vasudevan HN, Braunstein SE, Phillips JJ, Pekmezci M, Tomlin BA, Wu A, Reis GF, Magill ST, Zhang J, Feng FY, Nicholaides T, Chang SM, Sneed PK, McDermott MW, Berger MS, Perry A, Raleigh DR. PMID: 29590631; PMCID: PMC8204688.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
    328. Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study. J Clin Oncol. 2018 05 01; 36(13):1317-1322. Jagsi R, Griffith KA, Bellon JR, Woodward WA, Horton JK, Ho A, Feng FY, Speers C, Overmoyer B, Sabel M, Schott AF, Pierce L, Translational Breast Cancer Research Consortium. PMID: 29558281; PMCID: PMC6804907.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    329. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. 2018 08; 74(2):146-154. Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL. PMID: 29478736; PMCID: PMC6615042.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    330. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res. 2018 04; 16(4):643-654. Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM. PMID: 29453313; PMCID: PMC5882567.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    331. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. Ann Oncol. 2018 02 01; 29(2):386-391. Yang DD, Krasnova A, Nead KT, Choueiri TK, Hu JC, Hoffman KE, Yu JB, Spratt DE, Feng FY, Trinh QD, Nguyen PL. PMID: 29267861.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    332. Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):376-386. Dess RT, Devasia TP, Aghdam N, Jackson WC, Soni PD, Smith CP, Mitchell AL, Suy S, Hamstra DA, Jolly S, Nguyen PL, Feng FY, Schipper MJ, Skolarus TA, Miller DC, Wittmann DA, Collins SP, Spratt DE. PMID: 29487023.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    333. Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. Eur Urol. 2018 10; 74(4):413-419. Jackson WC, Suresh K, Tumati V, Allen SG, Dess RT, Salami SS, George A, Kaffenberger SD, Miller DC, Hearn JWD, Jolly S, Mehra R, Hollenbeck BK, Palapattu GS, Schipper M, Feng FY, Morgan TM, Desai NB, Spratt DE. PMID: 29306514.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    334. Self-reported Conflicts of Interest and Trial Sponsorship of Clinical Trials in Prostate Cancer Involving Radiotherapy. Am J Clin Oncol. 2018 Jan; 41(1):6-12. Moraes FY, Leite ETT, Hamstra DA, Feng FY, Arruda FF, Gadia R, Abreu CECV, Marta GN, Hanna SA, Silva JLFD, Carvalho HA, Spratt DE. PMID: 26703812.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    335. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018 04 01; 36(10):991-999. Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, Stadler WM, Feng FY, Chinnaiyan AM. PMID: 29261439; PMCID: PMC6075827.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCellsCTClinical Trials
    336. Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. Cell. 2017 Dec 14; 171(7):1559-1572.e20. Hosono Y, Niknafs YS, Prensner JR, Iyer MK, Dhanasekaran SM, Mehra R, Pitchiaya S, Tien J, Escara-Wilke J, Poliakov A, Chu SC, Saleh S, Sankar K, Su F, Guo S, Qiao Y, Freier SM, Bui HH, Cao X, Malik R, Johnson TM, Beer DG, Feng FY, Zhou W, Chinnaiyan AM. PMID: 29245011; PMCID: PMC5734106.
      View in: PubMed   Mentions: 125     Fields:    Translation:HumansAnimalsCells
    337. Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer. 2018 03 15; 124(6):1141-1149. Mahal BA, Chen YW, Sethi RV, Padilla OA, Yang DD, Chavez J, Muralidhar V, Hu JC, Feng FY, Hoffman KE, Martin NE, Spratt DE, Yu JB, Orio PF, Nguyen PL. PMID: 29231964.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    338. Differential impact of RB status on E2F1 reprogramming in human cancer. J Clin Invest. 2018 01 02; 128(1):341-358. McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Crespo M, De Laere B, Dirix L, Visakorpi T, Li F, Feng FY, de Bono J, Demichelis F, Rubin MA, Brown M, Knudsen KE. PMID: 29202480; PMCID: PMC5749518.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    339. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst. 2017 Dec 01; 109(12). Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. PMID: 29206995; PMCID: PMC6440274.
      View in: PubMed   Mentions: 176     Fields:    Translation:HumansCells
    340. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 12 01; 3(12):1663-1672. Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY. PMID: 28494073; PMCID: PMC5824281.
      View in: PubMed   Mentions: 136     Fields:    Translation:Humans
    341. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. J Clin Oncol. 2018 02 20; 36(6):581-590. Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL. PMID: 29185869; PMCID: PMC6530900.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    342. Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol 2018;73:156-65: Salvage Radiotherapy and Hormone Therapy: Change Is Coming, Just Not Quite Yet. Eur Urol. 2018 Mar; 73(3):e64-e65. Spratt DE, Dess RT, Feng FY. PMID: 29111144.
      View in: PubMed   Mentions:    Fields:    
    343. Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. Oncotarget. 2017 Oct 27; 8(52):89848-89866. Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA. PMID: 29163793; PMCID: PMC5685714.
      View in: PubMed   Mentions: 22     Fields:    
    344. LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. Cancer Res. 2017 10 15; 77(20):5479-5490. Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J, Ekram MB, Li B, Davicioni E, Takhar M, Erho N, Karnes RJ, Chadwick D, van der Kwast T, Boutros PC, Arrowsmith CH, Feng FY, Joshua AM, Zoubeidi A, Cai C, He HH. PMID: 28916652.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    345. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clin Cancer Res. 2017 Nov 15; 23(22):7072-7083. Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, Eng KH, Ellis L. PMID: 28899973; PMCID: PMC5690819.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    346. Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection. Adv Healthc Mater. 2018 02; 7(3). Shen MY, Chen JF, Luo CH, Lee S, Li CH, Yang YL, Tsai YH, Ho BC, Bao LR, Lee TJ, Jan YJ, Zhu YZ, Cheng S, Feng FY, Chen P, Hou S, Agopian V, Hsiao YS, Tseng HR, Posadas EM, Yu HH. PMID: 28892262; PMCID: PMC5803304.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    347. [Clinical research of minimally invasive spine surgery with Vesselplasty]. Zhonghua Yi Xue Za Zhi. 2017 Sep 05; 97(33):2567-2572. Tang H, Jia P, Chen H, Bao L, Feng F, Li JJ. PMID: 28881528.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    348. Co-expression of lipase isozymes for enhanced expression in Pichia pastoris. Lett Appl Microbiol. 2017 Oct; 65(4):335-342. Cai H, Zhang T, Zhao M, Mao J, Cai C, Feng F. PMID: 28763110.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    349. Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. NPJ Breast Cancer. 2017; 3:29. Speers C, Zhao SG, Chandler B, Liu M, Wilder-Romans K, Olsen E, Nyati S, Ritter C, Alluri PG, Kothari V, Hayes DF, Lawrence TS, Spratt DE, Wahl DR, Pierce LJ, Feng FY. PMID: 28840192; PMCID: PMC5562815.
      View in: PubMed   Mentions: 29  
    350. Erectile function after stereotactic body radiotherapy for localized prostate cancer. BJU Int. 2018 01; 121(1):61-68. Dess RT, Hartman HE, Aghdam N, Jackson WC, Soni PD, Abugharib AE, Suy S, Desai NB, Zumsteg ZS, Mehra R, Morgan TM, Feng FY, Hamstra DA, Schipper MJ, Collins SP, Spratt DE. PMID: 28710895.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    351. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. Pract Radiat Oncol. 2018 Jan - Feb; 8(1):40-47. Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng FY, Sandler HM, Wallace RE, Spratt DE, Hamstra DA. PMID: 29304991.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    352. Modulation of periodontitis progression using pH-responsive nanosphere encapsulating metronidazole or N-phenacylthialzolium bromide. J Periodontal Res. 2018 Feb; 53(1):22-28. Lin JH, Feng F, Yu MC, Wang CH, Chang PC. PMID: 28795395.
      View in: PubMed   Mentions: 11     Fields:    Translation:Animals
    353. Risk of low-energy fracture in type 2 diabetes patients: a meta-analysis of observational studies. Osteoporos Int. 2017 11; 28(11):3113-3121. Jia P, Bao L, Chen H, Yuan J, Liu W, Feng F, Li J, Tang H. PMID: 28795239.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    354. Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities. Immunotherapy. 2017 08; 9(9):695-699. Green M, Feng FY, Mehra R, Spratt DE. PMID: 28771102.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    355. High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir ≤0.2 to Select Men for Short-term Hormonal Therapy. Am J Clin Oncol. 2017 Aug; 40(4):348-352. Son CH, Hamstra DA, Feng FY, Liauw SL. PMID: 25436827.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    356. Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. Cancer Res. 2017 09 15; 77(18):4745-4754. Yin Y, Li R, Xu K, Ding S, Li J, Baek G, Ramanand SG, Ding S, Liu Z, Gao Y, Kanchwala MS, Li X, Hutchinson R, Liu X, Woldu SL, Xing C, Desai NB, Feng FY, Burma S, de Bono JS, Dehm SM, Mani RS, Chen BPC, Raj GV. PMID: 28754673; PMCID: PMC5600864.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    357. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. 2018 02; 73(2):156-165. Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY. PMID: 28716370.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    358. Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. Curr Urol Rep. 2017 Jul; 18(7):55. Dess RT, Morgan TM, Nguyen PL, Mehra R, Sandler HM, Feng FY, Spratt DE. PMID: 28589403.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    359. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 02; 73(2):178-211. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. PMID: 28655541.
      View in: PubMed   Mentions: 186     Fields:    Translation:Humans
    360. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer. Eur Urol Focus. 2019 01; 5(1):69-76. Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL. PMID: 28753811.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    361. Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications. Oncology (Williston Park). 2017 06 15; 31(6):467-74. Aggarwal RR, Feng FY, Small EJ. PMID: 28620903.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    362. Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. Proc Natl Acad Sci U S A. 2017 06 27; 114(26):E5207-E5215. Fei T, Chen Y, Xiao T, Li W, Cato L, Zhang P, Cotter MB, Bowden M, Lis RT, Zhao SG, Wu Q, Feng FY, Loda M, He HH, Liu XS, Brown M. PMID: 28611215; PMCID: PMC5495225.
      View in: PubMed   Mentions: 181     Fields:    Translation:HumansCells
    363. Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):274-284. Hall WA, Bergom C, Thompson RF, Baschnagel AM, Vijayakumar S, Willers H, Li XA, Schultz CJ, Wilson GD, West CML, Capala J, Coleman CN, Torres-Roca JF, Weidhaas J, Feng FY. PMID: 28964588.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    364. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Rep. 2017 06 06; 19(10):2045-2059. Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG. PMID: 28591577; PMCID: PMC5675034.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCells
    365. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urol Oncol. 2017 09; 35(9):542.e25-542.e32. Yang DD, Muralidhar V, Mahal BA, Nezolosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Den RB, Spratt DE, Hoffman KE, Feng FY, Nguyen PL. PMID: 28533151.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    366. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. Eur Urol. 2017 11; 72(5):845-852. Nguyen PL, Haddad Z, Ross AE, Martin NE, Deheshi S, Lam LLC, Chelliserry J, Tosoian JJ, Lotan TL, Spratt DE, Stoyanova RS, Punnen S, Ong K, Buerki C, Aranes M, Kolisnik T, Margrave J, Yousefi K, Choeurng V, Davicioni E, Trock BJ, Kane CJ, Pollack A, Davis JW, Feng FY, Klein EA. PMID: 28528811.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    367. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017 12; 58(12):1956-1961. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. PMID: 28522741.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    368. External beam radiation therapy with or without low-dose-rate brachytherapy: Analysis of favorable and unfavorable intermediate-risk prostate cancer patients. Brachytherapy. 2017 Jul - Aug; 16(4):782-789. Abugharib AE, Dess RT, Soni PD, Narayana V, Evans C, Gaber MS, Feng FY, McLaughlin PW, Spratt DE. PMID: 28499487.
      View in: PubMed   Mentions: 2     Fields:    
    369. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol. 2017 05 01; 28(5):1098-1104. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. PMID: 28453693.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    370. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017 09; 7(9):999-1005. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. PMID: 28450426; PMCID: PMC5581695.
      View in: PubMed   Mentions: 131     Fields:    Translation:Humans
    371. Characteristics and national trends of patients receiving treatment of the primary tumor for metastatic prostate cancer. Prostate Int. 2017 Sep; 5(3):89-94. Sinha S, Muralidhar V, Feng FY, Nguyen PL. PMID: 28828351; PMCID: PMC5551914.
      View in: PubMed   Mentions: 1  
    372. Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. J Clin Oncol. 2017 Jun 20; 35(18):1991-1998. Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, Trock BJ, Zhang J, Glass AG, Dicker AP, Abdollah F, Zhao SG, Lam LLC, du Plessis M, Choeurng V, Haddad Z, Buerki C, Davicioni E, Weinmann S, Freedland SJ, Klein EA, Karnes RJ, Feng FY. PMID: 28358655; PMCID: PMC6530581.
      View in: PubMed   Mentions: 80     Fields:    Translation:Humans
    373. Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. BJU Int. 2017 09; 120(3):351-357. Jackson WC, Desai NB, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, Zumsteg ZS, Sandler H, Hamstra DA, Montgomery JS, Miller DC, Kozminski MA, Hollenbeck BK, Hearn JW, Palapattu G, Tomlins SA, Mehra R, Morgan TM, Feng FY, Spratt DE. PMID: 28139024.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    374. National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):338-343. Yang DD, Muralidhar V, Mahal BA, Labe SA, Nezolosky MD, Vastola ME, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Spratt DE, Hoffman KE, Feng FY, Nguyen PL. PMID: 28463152.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    375. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017 02 02; 376(5):417-428. Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM, NRG Oncology RTOG. PMID: 28146658; PMCID: PMC5444881.
      View in: PubMed   Mentions: 225     Fields:    Translation:Humans
    376. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017 06; 20(2):186-192. Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY. PMID: 28117383; PMCID: PMC5435968.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    377. Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. Int J Radiat Oncol Biol Phys. 2017 07 15; 98(4):726-732. Wahl DR, Nguyen PL, Santiago M, Yousefi K, Davicioni E, Shumway DA, Speers C, Mehra R, Feng FY, Osborne JR, Spratt DE. PMID: 28258894.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    378. MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. Cancer Res. 2017 02 15; 77(4):1021-1034. Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, Zhao SG, Hanson AR, Pickering MA, Armstrong HK, Lokman NA, Ebrahimie E, Davicioni E, Jenkins RB, Karnes RJ, Ross AE, Den RB, Klein EA, Chi KN, Ramshaw HS, Williams ED, Zoubeidi A, Goodall GJ, Feng FY, Butler LM, Tilley WD, Selth LA. PMID: 28011622.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansAnimalsCells
    379. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. Cancer. 2017 05 01; 123(9):1635-1642. Dess RT, Jackson WC, Suy S, Soni PD, Lee JY, Abugharib AE, Zumsteg ZS, Feng FY, Hamstra DA, Collins SP, Spratt DE. PMID: 28001303.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    380. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis. Mol Cancer. 2016 12 12; 15(1):81. Tan M, Xu J, Siddiqui J, Feng F, Sun Y. PMID: 27955654; PMCID: PMC5153812.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    381. Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. Cancer Res. 2017 02 15; 77(4):960-970. Wahl DR, Dresser J, Wilder-Romans K, Parsels JD, Zhao SG, Davis M, Zhao L, Kachman M, Wernisch S, Burant CF, Morgan MA, Feng FY, Speers C, Lyssiotis CA, Lawrence TS. PMID: 27923831; PMCID: PMC5726266.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimalsCells
    382. RB Loss Promotes Prostate Cancer Metastasis. Cancer Res. 2017 02 15; 77(4):982-995. Thangavel C, Boopathi E, Liu Y, Haber A, Ertel A, Bhardwaj A, Addya S, Williams N, Ciment SJ, Cotzia P, Dean JL, Snook A, McNair C, Price M, Hernandez JR, Zhao SG, Birbe R, McCarthy JB, Turley EA, Pienta KJ, Feng FY, Dicker AP, Knudsen KE, Den RB. PMID: 27923835; PMCID: PMC5700768.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    383. Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis. Osteoporos Int. 2017 03; 28(3):1027-1034. Zhao R, Wang H, Wang X, Feng F. PMID: 27844132; PMCID: PMC7079838.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    384. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis. 2017 03; 20(1):28-35. Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, Hurley P, Bishop JL, Tosoian J, Ghabili K, Alshalalfa M, Glavaris S, Simons BW, Tran P, Davicioni E, Karnes RJ, Boudadi K, Antonarakis ES, Schaeffer EM, Drake CG, Feng F, Ross AE. PMID: 27801901; PMCID: PMC6512966.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCells
    385. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016 Oct 20; 34(30):3648-3654. Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ. PMID: 27528718.
      View in: PubMed   Mentions: 127     Fields:    
    386. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol. 2016 Nov; 17(11):1612-1620. Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng FY. PMID: 27743920.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansCells
    387. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. J Natl Cancer Inst. 2017 01; 109(1). Shukla S, Evans JR, Malik R, Feng FY, Dhanasekaran SM, Cao X, Chen G, Beer DG, Jiang H, Chinnaiyan AM. PMID: 27707839; PMCID: PMC5051943.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansCells
    388. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urol Case Rep. 2016 Nov; 9:51-54. Kim H, Alshalalfa M, Hoffman-Censits J, Lallas CD, Davicioni E, Lin J, Birbe R, Erho N, Lehrer J, Ashab HA, Takhar M, Olson A, Lam LL, Kelly WK, Knudsen KE, Thangavel C, Seiler R, Feng FY, Schaeffer EM, Trabulsi EJ, Gomella LG, Hurwitz MD, Dicker AP, Den RB. PMID: 27713863; PMCID: PMC5050262.
      View in: PubMed   Mentions:
    389. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun. 2016 09 26; 7:12791. Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, Prensner JR, Poliakov A, Singhal U, Xiao L, Kregel S, Siebenaler RF, Zhao SG, Uhl M, Gawronski A, Hayes DF, Pierce LJ, Cao X, Collins C, Backofen R, Sahinalp CS, Rae JM, Chinnaiyan AM, Feng FY. PMID: 27666543; PMCID: PMC5052669.
      View in: PubMed   Mentions: 126     Fields:    Translation:HumansCells
    390. Cell cycle-coupled expansion of AR activity promotes cancer progression. Oncogene. 2017 03 23; 36(12):1655-1668. McNair C, Urbanucci A, Comstock CE, Augello MA, Goodwin JF, Launchbury R, Zhao SG, Schiewer MJ, Ertel A, Karnes J, Davicioni E, Wang L, Wang Q, Mills IG, Feng FY, Li W, Carroll JS, Knudsen KE. PMID: 27669432; PMCID: PMC5364060.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    391. Comparison of clinicopathological features and prognosis of gastric cancer located in the lesser and greater curve. Clin Transl Oncol. 2017 Apr; 19(4):457-463. Feng F, Tian Y, Guo M, Liu S, Xu G, Liu Z, Zheng G, Lian X, Fan D, Zhang H. PMID: 27663247.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    392. Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy. Semin Radiat Oncol. 2017 01; 27(1):11-20. Hall WA, Lawton CA, Jani AB, Pollack A, Feng FY. PMID: 27986207.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    393. Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. J Urol. 2017 03; 197(3 Pt 1):662-668. Abugharib A, Jackson WC, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Zumsteg ZS, Mehra R, Feng FY, Morgan TM, Desai N, Spratt DE. PMID: 27614333.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    394. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):1046-1053. Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, Michalski JM, Feng FY, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ, Tendulkar RD. PMID: 27745980.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    395. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat Genet. 2016 10; 48(10):1142-50. Guo H, Ahmed M, Zhang F, Yao CQ, Li S, Liang Y, Hua J, Soares F, Sun Y, Langstein J, Li Y, Poon C, Bailey SD, Desai K, Fei T, Li Q, Sendorek DH, Fraser M, Prensner JR, Pugh TJ, Pomerantz M, Bristow RG, Lupien M, Feng FY, Boutros PC, Freedman ML, Walsh MJ, He HH. PMID: 27526323.
      View in: PubMed   Mentions: 125     Fields:    Translation:HumansAnimalsCells
    396. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy. 2016 Nov - Dec; 15(6):695-700. Chen YW, Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Choueiri TK, Hoffman KE, Martin NE, Orio PF, Sweeney CJ, Feng FY, Trinh QD, Nguyen PL. PMID: 27528590.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    397. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. Int J Radiat Oncol Biol Phys. 2016 11 15; 96(4):770-777. Lee JY, Daignault-Newton S, Heath G, Scarlett S, Sanda MG, Chang P, Regan MM, Michalski JM, Sandler HM, Feng FY, Kuban DA, Zietman AL, Ciezki JP, Kaplan ID, Crociani C, McLaughlin WP, Mantz CA, Finkelstein SE, Suy S, Collins SP, Garin O, Ferrer M, Hamstra DA, Spratt DE. PMID: 27663760.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    398. Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia. 2016 08; 18(8):489-99. Shukla S, Zhang X, Niknafs YS, Xiao L, Mehra R, Cieslik M, Ross A, Schaeffer E, Malik B, Guo S, Freier SM, Bui HH, Siddiqui J, Jing X, Cao X, Dhanasekaran SM, Feng FY, Chinnaiyan AM, Malik R. PMID: 27566105; PMCID: PMC5018094.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    399. The bright side of dark matter: lncRNAs in cancer. J Clin Invest. 2016 08 01; 126(8):2775-82. Evans JR, Feng FY, Chinnaiyan AM. PMID: 27479746; PMCID: PMC4966302.
      View in: PubMed   Mentions: 227     Fields:    Translation:HumansAnimalsCells
    400. Racial/Ethnic Disparities in Genomic Sequencing. JAMA Oncol. 2016 Aug 01; 2(8):1070-4. Spratt DE, Chan T, Waldron L, Speers C, Feng FY, Ogunwobi OO, Osborne JR. PMID: 27366979; PMCID: PMC5123755.
      View in: PubMed   Mentions: 160     Fields:    Translation:Humans
    401. National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer. 2016 Nov 15; 122(21):3371-3377. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. PMID: 27434225.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    402. Reply to Yu-Wen Hu's Letter to the Editor re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50-7. Eur Urol. 2016 12; 70(6):e159. Jackson WC, Schipper MJ, Feng FY. PMID: 27210457.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    403. [Association between cured meat consumption and risk of colorectal cancer in people with different dietary habits and lifestyles]. Zhonghua Liu Xing Bing Xue Za Zhi. 2016 Jul; 37(7):1006-11. Li YL, Feng F, Yan J, Chen LL, Li XL, Liu WH, Yang YF. PMID: 27453114.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    404. Long noncoding RNAs in prostate cancer: overview and clinical implications. Asian J Androl. 2016 Jul-Aug; 18(4):568-74. Malik B, Feng FY. PMID: 27072044; PMCID: PMC4955180.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    405. Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol. 2016 10; 13(10):597-610. Spratt DE, Zumsteg ZS, Feng FY, Tomlins SA. PMID: 27245282; PMCID: PMC5030163.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    406. Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer. Clin Cancer Res. 2016 Dec 01; 22(23):5864-5875. Speers C, Zhao SG, Kothari V, Santola A, Liu M, Wilder-Romans K, Evans J, Batra N, Bartelink H, Hayes DF, Lawrence TS, Brown PH, Pierce LJ, Feng FY. PMID: 27225691; PMCID: PMC8820108.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimalsCells
    407. Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up. Prostate Cancer Prostatic Dis. 2016 09; 19(3):292-7. Spratt DE, Jackson WC, Abugharib A, Tomlins SA, Dess RT, Soni PD, Lee JY, Zhao SG, Cole AI, Zumsteg ZS, Sandler H, Hamstra D, Hearn JW, Palapattu G, Mehra R, Morgan TM, Feng FY. PMID: 27215611.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    408. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Ann Oncol. 2016 09; 27(9):1706-12. Udager AM, Liu TY, Skala SL, Magers MJ, McDaniel AS, Spratt DE, Feng FY, Siddiqui J, Cao X, Fields KL, Morgan TM, Palapattu GS, Weizer AZ, Chinnaiyan AM, Alva A, Montgomery JS, Tomlins SA, Jiang H, Mehra R. PMID: 27217541; PMCID: PMC4999561.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    409. Predictors of Dysgeusia in Patients With Oropharyngeal Cancer Treated With Chemotherapy and Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 10 01; 96(2):354-361. Sapir E, Tao Y, Feng F, Samuels S, El Naqa I, Murdoch-Kinch CA, Feng M, Schipper M, Eisbruch A. PMID: 27473816.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    410. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer Prostatic Dis. 2016 09; 19(3):277-82. Ross AE, Den RB, Yousefi K, Trock BJ, Tosoian J, Davicioni E, Thompson DJ, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, Klein EA, Dicker AP, Freedland SJ, Karnes RJ, Schaeffer EM. PMID: 27136742; PMCID: PMC5411670.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    411. Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urol Oncol. 2016 09; 34(9):415.e1-6. Kozminski MA, Tomlins S, Cole A, Singhal U, Lu L, Skolarus TA, Palapattu GS, Montgomery JS, Weizer AZ, Mehra R, Hollenbeck BK, Miller DC, He C, Feng FY, Morgan TM. PMID: 27140065.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    412. Independent surgical validation of the new prostate cancer grade-grouping system. BJU Int. 2016 Nov; 118(5):763-769. Spratt DE, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS, Dess RT, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng FY, Mehra R, Morgan TM. PMID: 27009882.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    413. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. J Natl Compr Canc Netw. 2016 04; 14(4):421-8. Muralidhar V, Catalano PJ, Reznor G, Mahal BA, Choueiri TK, Sweeney CJ, Martin NE, Beard CJ, Chen YW, Nezolosky MD, Hoffman KE, Feng FY, Trinh QD, Nguyen PL. PMID: 27059190.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    414. Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation Therapy. Am J Clin Oncol. 2016 Apr; 39(2):173-80. Vainshtein JM, Schipper M, Vance S, Feng FY, Olson KB, Hamstra DA. PMID: 24487421.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    415. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncol. 2016 Apr; 2(4):471-80. Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, Rubin MA, de Bono J, Knudsen KE, Davicioni E, Feng FY. PMID: 26746117; PMCID: PMC5469505.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    416. Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. Eur Urol Focus. 2016 Dec; 2(5):532-539. Spratt DE, Chen YW, Mahal BA, Osborne JR, Zhao SG, Morgan TM, Palapattu G, Feng FY, Nguyen PL. PMID: 28723519.
      View in: PubMed   Mentions: 13     Fields:    
    417. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. Neoplasia. 2016 04; 18(4):213-22. Feng FY, Zhang Y, Kothari V, Evans JR, Jackson WC, Chen W, Johnson SB, Luczak C, Wang S, Hamstra DA. PMID: 27108384; PMCID: PMC4840291.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    418. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer. 2016 05 15; 122(10):1505-12. Mahal BA, Chen YW, Efstathiou JA, Muralidhar V, Hoffman KE, Yu JB, Feng FY, Beard CJ, Martin NE, Orio PF, Nguyen PL. PMID: 26970022.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    419. Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy. Prostate Cancer Prostatic Dis. 2016 06; 19(2):216-21. Morgan TM, Hawken SR, Ghani KR, Miller DC, Feng FY, Linsell SM, Salisz JA, Gao Y, Montie JE, Cher ML. PMID: 26951715.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    420. Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. J Contemp Brachytherapy. 2016 Feb; 8(1):1-6. Muralidhar V, Xiang M, Orio PF, Martin NE, Beard CJ, Feng FY, Hoffman KE, Nguyen PL. PMID: 26985191; PMCID: PMC4793071.
      View in: PubMed   Mentions: 8  
    421. Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. J Urol. 2016 08; 196(2):405-11. Cole AI, Morgan TM, Spratt DE, Palapattu GS, He C, Tomlins SA, Weizer AZ, Feng FY, Wu A, Siddiqui J, Chinnaiyan AM, Montgomery JS, Kunju LP, Miller DC, Hollenbeck BK, Wei JT, Mehra R. PMID: 26920466.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    422. microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients. Mol Biol Rep. 2016 Apr; 43(4):229-40. Bakkar A, Alshalalfa M, Petersen LF, Abou-Ouf H, Al-Mami A, Hegazy SA, Feng F, Alhajj R, Bijian K, Alaoui-Jamali MA, Bismar TA. PMID: 26907180.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells